aspirin has been researched along with adenosine in 332 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (15.06) | 18.7374 |
| 1990's | 14 (4.22) | 18.2507 |
| 2000's | 20 (6.02) | 29.6817 |
| 2010's | 232 (69.88) | 24.3611 |
| 2020's | 16 (4.82) | 2.80 |
| Authors | Studies |
|---|---|
| Campillo, N; Carrasco, E; García, C; Goya, P; Grau, M; Páez, JA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Asker, AF; Whitworth, CW | 2 |
| Tsukada, T | 1 |
| Glusa, E; Hoffmann, A | 1 |
| Rosenberg, JC; Sell, TL | 1 |
| Rosenberg, JC; Sell, T | 1 |
| CoFrancesco, E; Deliliers, GL; Ferrari, R; Pogliani, E; Pozzoli, E; Praga, C | 1 |
| Yasunaga, K | 1 |
| Fujitani, B; Shimizu, M; Tsuboi, T; Yoshida, K | 1 |
| Chuang, HY; Crowther, PE; Mason, RG; Mohammad, SF | 1 |
| Cameron, JS; Clark, WF; George, CR | 1 |
| Ku, CS; Wu, KK | 1 |
| Kato, T; Umetsu, T | 1 |
| Jenkins, CS; Oosterhuis, H; Prenger, D; ten Cate, JW; Vos, J | 1 |
| Kuramoto, A; Taketomi, Y | 1 |
| Clawson, CC; Rao, GH; White, JG | 1 |
| Hoak, JC; Wu, KK | 1 |
| Ts'ao, C | 1 |
| Fujitani, B; Shimizu, M; Takeno, K; Tsuboi, T; Yoshida, K | 1 |
| Garg, KN; Gupta, LC; Singh, J; Sudhir, S | 1 |
| Barbenel, JC; Forbes, CD; Lowe, GD; Madhok, R; Saniabadi, AR; Shaw, B; Spowart, K | 1 |
| Feinberg, H; Lee, SL; Levitsky, S | 1 |
| Grover, GJ; Schumacher, WA | 1 |
| Altman, R; Scazziota, A | 1 |
| Anselone, CG; Bristow, JD; Johnson, WB; Pantely, GA; Seaman, GV; Swenson, LJ; Tamblyn, CH | 1 |
| Blockmans, D; Bounameaux, H; Vermylen, J; Verstraete, M | 1 |
| Huang, TF; Yang, BB | 1 |
| Glusa, E; Markwardt, F | 1 |
| Weiss, HJ | 2 |
| Ingerman, C; Kocsis, JJ; Silver, MJ; Smith, JB | 1 |
| De Gaetano, G; Donati, MB; Vermylen, J | 1 |
| Salzman, EW; Weisenberger, H | 1 |
| Deykin, D; Hardisty, RM; Howard, MA; Hutton, RA | 1 |
| Gerrard, JM; Rao, GH; White, JG | 1 |
| Kuhn, DC; Petrin, M; Scott, CG; Vane, FM; Willis, AL | 1 |
| Born, GV | 1 |
| Hardisty, RM | 1 |
| Eika, C | 1 |
| Glusa, E | 1 |
| Banks, DC; Mitchell, JR | 1 |
| Freuler, F; Smith, GM | 1 |
| Borrelli, F; Caprino, L; Falchetti, R | 1 |
| Barr, RD; Douglas, AS; Forbes, CD; McNicol, GP | 1 |
| Begent, NA; Born, GV | 1 |
| De Gaetano, G; Vermylen, J; Verstraete, M | 1 |
| Files, JC; Harker, LA; Malpass, TW; Ritchie, JL; Yee, EK | 1 |
| Dudley, FJ; Firkin, BG; Handley, C; Koutts, J; Salem, HH; van Der Weyden, MB | 1 |
| Agarwal, K; Kane, RL; Richardson, PD | 1 |
| Miyazaki, M; Okunishi, H; Taniyama, K; Toda, N | 1 |
| Mustafa, SJ | 1 |
| Bullough, DA; Montag, A; Mullane, KM; Young, MA; Zhang, C | 1 |
| Belzer, FO; Saunder, A; Southard, JH | 1 |
| Bastida, E; Bozzo, J; Escolar, G; Hernández, MR; Ordinas, A | 1 |
| Lind, SE; Vasconcellos, CA | 1 |
| Amici, D; Bramucci, M; Gobbetti, A; Miano, A; Murri, O; Zerani, M | 1 |
| Ciccarelli, A; de Crescenzo, G; de Paulis, A; Marinò, D; Marinò, I; Marone, G | 1 |
| Belzer, FO; Saunder, A; Schilling, M; Southard, JH | 1 |
| Lavallée, M; Ming, Z; Parent, R | 1 |
| Fredholm, BB | 1 |
| Abbracchio, MP; Picano, E | 1 |
| Girouard, H; Savard, R | 1 |
| Castle, SF; Duffy, SJ; Harper, RW; Meredith, IT | 1 |
| Bergmann, SR | 2 |
| Anderson, JD; Littmann, L; Monroe, MH | 1 |
| Kato, S; Komoike, Y; Takeeda, M; Takeuchi, K; Tanaka, A | 1 |
| Kopff, A; Kopff, M; Kowalczyk, E | 1 |
| Abraham, R; Biaggioni, I; Diedrich, A; Farley, G; Gamboa, A; Paranjape, SY; Shibao, C | 1 |
| Emanuelsson, H; Heptinstall, S; Husted, S; Peters, G; Sandset, PM; Wickens, M | 1 |
| Gurbel, PA; Tantry, US | 1 |
| Roe, MT; Steinhubl, S | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF | 1 |
| Barker, CM; Price, MJ | 1 |
| Angiolillo, DJ; Guzman, LA | 1 |
| Eikelboom, JW; Hirsh, J; Raju, NC | 1 |
| Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Butt, M; Lip, GY; Shantsila, E; Siddique, A | 1 |
| Kumar, A; Roberts, DH | 1 |
| Collet, JP; Montalescot, G | 1 |
| Antonino, MJ; Bliden, KP; Butler, K; Gesheff, T; Gurbel, PA; Karunakaran, A; Kereiakes, DJ; Ledley, GS; Parris, C; Patil, SB; Purdy, D; Storey, RF; Tantry, US; Teng, R; Wei, C; Wilson, V | 1 |
| Antonijević, N; Antović, J; Baskot, B; Djenić, N; Dopudja, M; Gligić, B; Grdenić, A; Jovelić, A; Miković, D; Obradović, S; Salinger, S; Subota, V; Vukotić, S | 1 |
| Gyu Jeon, S; Kim, YK; Kim, YS; Moon, HG; Oh, SY; Song Gho, Y; Tae, YM; Zhu, Z | 1 |
| Aylward, PE; Behan, MW; Chew, DP | 1 |
| Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Storey, RF | 1 |
| Chew, DP; Prakash, R; Wong, YW | 1 |
| Erdem, G; Flather, MD; Geisler, T | 1 |
| Cairns, JA; Eikelboom, JW; Hirsh, J; Paikin, JS | 1 |
| Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C | 1 |
| Gratsianskiĭ, NA | 1 |
| Aïssaoui, N; Danchin, N | 1 |
| Abergel, E; Nikolsky, E | 1 |
| Pollack, CV | 1 |
| Capranzano, P; Dangas, G; Mehran, R; Stone, GW; Tamburino, C | 1 |
| Armstrong, M; Bliden, KP; Butler, K; Gurbel, PA; Storey, RF; Tantry, US; Wei, C | 1 |
| Frey, N; Ivandic, B | 1 |
| Ağırbaşlı, M; Cinçin, A; Güvenç, H | 1 |
| Buffet, P; Cottin, Y; Gudjoncik, A; L'Huillier, I; Lorgis, L; Richard, C; Zeller, M | 1 |
| Gaglia, MA; Waksman, R | 1 |
| Cattaneo, M | 1 |
| Hamm, CW; Rassaf, T | 1 |
| Serebruany, VL | 2 |
| White, HD | 1 |
| Berger, PB; Good, CW | 1 |
| Buyse, M; Marschner, IC | 1 |
| Moliterno, DJ; Rajan, L | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Carroll, K; Harrington, RA; Held, C; Horrow, J; James, S; Mahaffey, KW; Pieper, KS; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Bliden, KP; Gesheff, M; Gurbel, PA; Jeong, YH; Storey, RF; Tantry, US; Wei, C | 1 |
| Hinneburg, I | 1 |
| Chan, MV; Kirkby, NS; Leadbeater, PD; Mitchell, JA; Nylander, S; Warner, TD | 1 |
| Traynor, K | 1 |
| Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J | 2 |
| Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM | 1 |
| Basra, SS; Lakkis, NM; Tsai, P | 1 |
| Jeger, R; Kaiser, C; Pfisterer, M | 1 |
| Braunwald, E | 1 |
| Contractor, H; Ruparelia, N | 1 |
| Lavi, R; Lavi, S | 1 |
| Angiolillo, DJ; Azmoon, S | 1 |
| Heptinstall, S; Joshi, R; Wijeyeratne, YD | 1 |
| Ahmad, S; Storey, RF | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A | 1 |
| Huber, K | 1 |
| Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A | 1 |
| Kiss, RG | 1 |
| Butler, K; Maya, J; Teng, R | 1 |
| Htun, WW; Steinhubl, SR | 1 |
| Asanin, M; Brdar, N; Cvetinovic, N; Djuricic, N; Krljanac, G; Marinkovic, J; Mrdovic, I; Perunicic, J; Savic, L; Stankovic, S; Stojanovic, M | 1 |
| Aronow, WS | 1 |
| Björkman, JA; Forsberg, GB; Hansson, GI; Nylander, S; von Bahr, H; Warner, TD; Zachrisson, H | 1 |
| Agewall, S; Andreotti, F; Atar, D; Cattaneo, M; Collet, JP; Grove, EL; Huber, K; Husted, S; Kjeldsen, K; Lip, GY; Morais, J; Pathak, A; Rosano, G; Storey, RF; Verheugt, FW; Wassmann, S | 1 |
| DiNicolantonio, JJ; Serebruany, VL | 1 |
| James, S | 1 |
| Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C | 1 |
| Gurbel, PA; Jeong, YH; Kubica, J; Navarese, EP; Tantry, US | 1 |
| Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K | 1 |
| DiNicolantonio, JJ; Serebruany, VL; Tomek, A | 1 |
| Berger, JS | 1 |
| Fabiszak, T; Grzesk, E; Grześk, G; Gurbel, PA; Jeong, YH; Kozinski, M; Kubica, J; Navarese, EP; Tantry, US; Wicinski, M | 1 |
| Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL | 1 |
| Dinicolantonio, JJ; Norgard, NB | 1 |
| Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G | 1 |
| Grove, EL; Würtz, M | 2 |
| Clavijo, L; Gaglia, MA | 1 |
| Curkovic, I; Egbring, M; Kullak-Ublick, GA | 1 |
| Gasche, D; Greiner, RA; Meier, B; Ulle, T | 1 |
| Acharji, S; Kaluski, E; Lakshmanadoss, U; Rudzinski, W; Stapleton, DD | 1 |
| Adsett, G; Jayasinghe, R; Markham, R | 1 |
| Albertsson, P; Åström-Olsson, K; Dellborg, M; Hansson, EC; Hesse, C; Jeppsson, A; Shams Hakimi, C; Wallén, H | 1 |
| Arrich, J; Gouya, G; Gurbel, PA; Huber, K; Pirker-Kees, A; Siller-Matula, JM; Verheugt, FW; Wolzt, M | 1 |
| Bauer, M; Bräuer, A; Danner, BC; Hinz, J; Meyer, K; Mohite, PN; Popov, AF; Schöndube, FA; Schotola, H; Sossalla, S | 1 |
| Arntz, HR; Boudriot, E; Garlichs, C; Helms, TM; Hoffmann, S; Ince, H; Klingenheben, T; Schäfer, A; Silber, S; Weil, J; Zugck, C | 1 |
| Hirschl, MM | 1 |
| Cheng, VE; Haikerwal, D; Natarajan, D; Oppermen, A; Pereira, J | 1 |
| Gupta, K; Singh, D; Vacek, JL | 1 |
| Diamantopoulos, A; Karnabatidis, D; Katsanos, K; Kitrou, P; Pastromas, G; Siablis, D; Spiliopoulos, S | 1 |
| Edwards, MG; O'Shea, JP; Starac, D; Waterer, GW; Whitmore, TJ | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Held, P; Jensen, EC; Sabatine, MS; Steg, PG; Storey, RF | 1 |
| Al-Attar, N; Amour, J; Ascione, R; Collet, JP; Falk, V; Huber, K; Leite-Moreira, AF; Sousa-Uva, M; Storey, R; Taggart, D | 1 |
| Er Ching, M; Ho, HH; Ong, PJ; Ooi, YW | 1 |
| Bangalore, S; Biondi-Zoccai, G; Cerrato, E; Chatterjee, S; D'Ascenzo, F; DiNicolantonio, JJ; Fuchs, FD; Lavie, CJ; Meier, P; Niazi, AK; Norgard, NB; O'Keefe, JH; Packard, KA; Serebruany, VL | 1 |
| Asher, CR; Buitrago, I; Wolinsky, D | 1 |
| Droppa, M; Gawaz, M; Geisler, T; Karathanos, A; Metzger, J; Müller, K; Rath, D; Schäffeler, E; Schwab, M; Stimpfle, F; Tavlaki, E; Winter, S | 1 |
| Abbate, R; Antoniucci, D; Bellandi, B; Carrabba, N; Gensini, GF; Giurlani, L; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R | 1 |
| Emanuelsson, H; Hiasa, Y; Teng, R | 1 |
| Alraies, MC | 1 |
| Asher, C; Buitrago, I; Wolinsky, D | 1 |
| Birnbaum, Y; Kodakandla, M; Ling, S; Nanhwan, MK; Nylander, S; Ye, Y | 1 |
| Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E | 1 |
| Baber, U; Badimon, JJ; Crippa, M; Giannarelli, C; Mehran, R; Rodriguez, D; Sartori, S; Tewar, MP; Vorchheimer, DA; Zafar, MU | 1 |
| Adlam, D; Choudhury, RP; Hadley, G; Harrison, P | 1 |
| Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P | 1 |
| Fauchère, I; Schreiber, P; Wyss, C | 1 |
| Eichinger, S; Gouya, G; Kapiotis, S; Kyrle, PA; Litschauer, B; Mayer, P; Smerda, L; Weisshaar, S; Wolzt, M | 1 |
| Vengoechea, F | 1 |
| Dankiewicz, J; Friberg, H; Kander, T; Schött, U | 1 |
| Agostoni, P; Stella, PR; Timmers, L | 1 |
| Christ, G; Dechant, C; Francesconi, M; Grohs, K; Podczeck-Schweighofer, A; Siller-Matula, JM | 1 |
| Brokopp, J; Erlinge, D; Kander, T; Lood, C; Schött, U | 1 |
| Anderson, JL; Bates, ER; Bode, C; Granger, CB; Huber, K; Kristensen, SD; Lopez Sendon, JL; Ohman, EM; Steg, PG; Tubaro, M; Valgimigli, M; Wallentin, L | 1 |
| Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H | 1 |
| Chen, L; Fu, C; Lu, W; Ma, G; Wang, Y; Yao, Y; Zuo, P | 1 |
| Cho, JH; Ihm, CG; Jeong, KH; Kim, JB; Kim, KS; Kim, W; Kim, WS; Lee, TW; Woo, JS | 1 |
| Amsallem, M; Bal dit Sollier, C; Dillinger, JG; Drouet, L; Henry, P; Manzo-Silberman, S; Sideris, G; Voicu, S | 1 |
| Bansilal, S; Bengtsson, O; Bhatt, DL; Bonaca, MP; Braunwald, E; Budaj, A; Cohen, M; Fish, MP; Goto, S; Hamm, C; Held, P; Im, K; Jensen, EC; Kiss, RG; Magnani, G; Murphy, SA; Nicolau, JC; Oude Ophuis, T; Ruda, M; Sabatine, MS; Spinar, J; Steg, PG; Storey, RF; Theroux, P; Wiviott, SD | 1 |
| Keaney, JF | 1 |
| Steg, PG; Wiviott, SD | 1 |
| Kafkas, NV; Liakos, CI; Mouzarou, AG | 1 |
| Heitmeier, S; Laux, V; Perzborn, E | 1 |
| Aspromonte, N; Caldarola, P; Chiatto, M; Iacoviello, M; Monitillo, F; Valle, R | 1 |
| Ciccone, A; Mariani, R; Marinangeli, F | 1 |
| Cho, YR; Guo, LZ; Jin, CD; Kim, MH; Kim, YD; Lee, YS; Park, JS; Park, K; Park, TH | 1 |
| Al-Kindi, SG; Benatti, RD; Deo, S; ElAmm, C; Ginwalla, M; Medalion, B; Oliveira, GH; Osman, MN; Park, SJ; Qattan, MY; Simon, DI | 1 |
| Gao, F; Liu, XL; Shen, H; Wang, ZJ; Yang, SW; Zhou, YJ | 1 |
| Bonhomme, F; Cartier Faessler, V; Fontana, P; Maillard, J | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M | 6 |
| Andersson, M; Gustafsson, D; Nylander, S; Skärby, T; Wågberg, F | 1 |
| Angiolillo, DJ; Caplan, RJ; Carlson, GF; Ferdinand, KC; Maya, J; Teng, R; Waksman, R | 1 |
| Guimarães, PO; Tricoci, P | 1 |
| Ahmed, Z; Bajwa, A; Bhardwaj, B; Laster, SB; Magalski, A | 1 |
| Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M | 1 |
| Buccheri, S; Capodanno, D; Capranzano, P; Tamburino, C | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wong, LK | 1 |
| Chen, Y; Cong, H; Dong, W; Hong, T; Li, Z; Wan, Z; Yin, T | 1 |
| Bachelot-Loza, C; Berndt, C; Calmette, L; Decouture, B; Gaussem, P; Godier, A; Gouin-Thibault, I; Martin, AC; Philip, I; Samama, CM | 1 |
| Al Khalifa, A; Al Shouli, S; Bonneau, C; Chung, J; Currie, ME; Fagan, A; Lee, MM; Mewhort, HE; Ruel, M; Teoh, H; Verma, S; White, CW; Yamashita, MH; Yanagawa, B | 1 |
| Borghesi, M; D'Amico, G; Musumeci, G; Parodi, G; Tarantini, G | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Suryapranata, H; Verdoia, M | 1 |
| Cabrera-Fuentes, HA; Cherepanov, V; Kim, MH; Serebruany, VL | 1 |
| Choi, JH; Chon, MK; Chun, KJ; Han, DC; Han, J; Hwang, J; Hwang, KW; Jeong, YH; Kim, CH; Kim, IS; Kim, JH; Kim, JS; Lee, SH; Lee, SM; Lee, SY; Noh, M; Park, DW; Park, YH; Sohn, CB | 1 |
| Garcia-Garcia, HM; Hamm, C; Jüni, P; Serruys, PW; Steg, PG; Valgimigli, M; van Es, GA; Vranckx, P; Windecker, S | 1 |
| Jacquemyn, Y; Mannaerts, D; Muys, J; Verbruggen, M | 1 |
| Bougouin, W; Cariou, A; Dumas, F; Gouffran, G; Jakamy, R; Joffre, J; Lamhaut, L; Rosencher, J; Varenne, O | 1 |
| Dobesh, PP; Doyle, M; Varnado, S | 1 |
| Eichinger, S; Kaider, A; Kollars, M; Kyrle, PA; Traby, L; Wolzt, M | 1 |
| Chava, S; Schneider, DJ | 1 |
| Abacı, A; Aygencel, G; Kara, İ; Okuyan, H; Türkoğlu, M; Yıldırım, F | 1 |
| Parker, WA; Storey, RF | 1 |
| Bernstein, V; Cairns, J; Mancini, GB; Mayo, J; Saw, J; Skarsgard, P; Starovoytov, A; Wong, GC; Ye, J | 1 |
| Cherian, T; Devlin, G; Green, SA; Lee, M | 1 |
| Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX | 1 |
| Geissel, W | 1 |
| Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R | 1 |
| Aggarwal, N; Angiolillo, DJ; Antoun, P; Bass, TA; Been, L; Cho, JR; Durairaj, A; Faz, GT; Franchi, F; Guzman, LA; Hu, J; Kureti, M; Park, Y; Rollini, F; Suryadevara, S; Thano, E; Zenni, MM | 1 |
| Carlson, GF; Guo, J; Li, H; Teng, R | 1 |
| Abola, MTB; Aylward, P; Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Corbalán, R; Dalby, A; Dellborg, M; Goodrich, E; Held, P; Jensen, EC; Kuder, J; López-Sendón, J; Nicolau, JC; Parkhomenko, A; Sabatine, MS; Špinar, J; Steg, PG; Storey, RF | 1 |
| Ruiz-Nodar, JM | 1 |
| Dégano, IR; Elosua, R; Grau, M; Marrugat, J; Sayols-Baixeras, S | 1 |
| Bonello, L; Dignat-Georges, F; Fromonot, J; Guieu, R; Kipson, N; Mottola, G; Paganelli, F; Rossi, P; Ruf, J | 1 |
| Katsi, V; Tousoulis, D; Toutouzas, K; Trantalis, G | 1 |
| Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KS | 2 |
| Broe, A; Diness, TG; Emneus, M; Gislason, GH; Green, A; Hasvold, P; Pottegård, A | 1 |
| de Mol, BA; Li, WW; Manshanden, JS; Schotborgh, MA; Tomšič, A | 1 |
| Barbieri, L; Bellomo, G; De Luca, G; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M | 1 |
| Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S | 1 |
| Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD | 1 |
| Abu-Much, A; Asher, E; Atar, S; Beigel, R; Goldenberg, I; Matetzky, S; Mazin, I; Polak, A; Sabbag, A; Segev, A; Shlezinger, M; Zahger, D | 1 |
| Chung, SC; Denaxas, S; Emmas, C; Hemingway, H; Moayyeri, A; Pasea, L; Pujades-Rodriguez, M; Rapsomaniki, E; Shah, AD; Stogiannis, D; Timmis, A | 1 |
| Goudevenos, JA; Ntalas, IV; Tatsidou, PT; Tselepis, AD; Tsoumani, ME | 1 |
| Cattaneo, M; Cipriani, M; Femia, EA; Frigerio, M; Morici, N; Oliva, F; Perna, E | 1 |
| Gearman, DJ; Ingimarsson, JP; Krambeck, AE; Scales, J; Sharma, V; Westerman, ME | 1 |
| Barbieri, L; Brouwer, MA; Camaro, C; Damen, SA; de Boer, MJ; De Luca, G; Kedhi, E; Lee, SW; Ligtenberg, E; Rognoni, A; Suryapranata, H; van T Hof, AW; Verdoia, M | 1 |
| Wise, J | 1 |
| Priglinger, ML | 1 |
| Bhatt, DL; Bonaca, MP; Braunwald, E; Cohen, M; Dalby, AJ; Goodrich, E; Goto, S; Held, P; Hu, D; Jensen, E; Mauri, L; Morrow, DA; Ophuis, TO; Ruda, M; Sabatine, MS; Seung, KB; Špinar, J; Steg, PG; Storey, RF | 1 |
| Attmann, T; Beyersdorf, F; Boening, A; Cremer, J; Danner, BC; de Waha, A; Fischlein, T; Goerlach, G; Hambrecht, R; Hamm, C; Hammel, D; Joost, A; Kastrati, A; Knosalla, C; Koch-Buettner, K; Lange, R; Laufer, G; Misfeld, M; Mohr, FW; Oberhoffer, M; Putman, LM; Radke, PW; Sandner, S; Schmoeckel, M; Schöndube, FA; Schönrath, F; Schulz, R; Schunkert, H; Siepe, M; Sievers, HH; von Scheidt, M; Walther, T; Zeymer, U; Ziegelhöffer, T | 1 |
| Barillà, F; Borzi, M; Camici, P; Cas, LD; Di Biase, M; Filardi, PP; Indolfi, C; Mercuro, G; Montemurro, V; Padeletti, L; Pelliccia, F; Romeo, F; Vizza, CD | 1 |
| Bancone, C; Biancari, F; Chocron, S; Dalén, M; De Feo, M; Dominici, C; Faggian, G; Fischlein, T; Gatti, G; Gherli, R; Gherli, T; Gulbins, H; Kinnunen, EM; Mariscalco, G; Maschietto, L; Maselli, D; Mignosa, C; Musumeci, F; Nicolini, F; Onorati, F; Perrotti, A; Reichart, D; Rosato, S; Rubino, AS; Ruggieri, VG; Santarpino, G; Santini, F; Svenarud, P; Verhoye, JP; Zanobini, M | 1 |
| Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A | 1 |
| Gurbel, PA; Kubica, J; Myat, A; Tantry, US | 1 |
| Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC | 1 |
| Angiolillo, DJ; Aquino, M; Baber, U; Badimon, J; Chandrasekhar, J; Cohen, DJ; Dangas, G; Gibson, CM; Kastrati, A; Krucoff, MW; Mehran, R; Mehta, SR; Ohman, EM; Pocock, SJ; Sartori, S; Steg, PG; Zafar, MU | 1 |
| Kola, N; Mattiello, G; Mirra, M; Morisco, C; Spinelli, L | 1 |
| Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J | 1 |
| Barbour, C; Gesheff, T | 1 |
| Avgerinos, E; Bakoyiannis, C; Moris, D | 1 |
| Johnston, SC; Wang, Y | 1 |
| Albers, GW; Amarenco, P; Denison, H; Easton, JD; Evans, SR; Held, P; Hill, MD; Johnston, SC; Jonasson, J; Kasner, SE; Ladenvall, P; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL | 2 |
| Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M | 1 |
| Coons, JC; Iasella, CJ; Kane-Gill, SL; Verlinden, NJ | 1 |
| Armstrong, PC; Chan, MV; Ferreira, PM; Hayman, MA; Hoefer, T; Knowles, RB; Tucker, AT; Warner, TD | 1 |
| Almquist, J; Gennemark, P; Goodman, J; Janefeldt, A; Johansson, KJ; Maqbool, S; Nylander, S; Pehrsson, S; Sanchez, J; Sandinge, AS | 1 |
| Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J | 1 |
| Carr, K; Ghamasaee, P; Grandhi, R; Johnson, J | 1 |
| Becker, RC; Cannon, CP; Hagström, E; Himmelmann, A; James, SK; Katus, HA; Lindholm, D; López-Sendón, JL; Maurer, G; Siegbahn, A; Steg, PG; Storey, RF; Wallentin, L | 1 |
| Eichelberger, B; Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Panzer, S; Pultar, J; Seidinger, D; Wadowski, PP | 1 |
| Bellomo, G; Carriero, A; Daffara, V; De Luca, G; Marino, P; Pergolini, P; Rolla, R; Verdoia, M | 1 |
| Baber, U; Vogel, B | 1 |
| Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V | 1 |
| Godier, A; Houssany-Pissot, S; Martin, AC; Taylor, G; Zlotnik, D | 1 |
| Han, X; Jing, Q; Li, R; Tang, X; Wang, Q; Yang, M; Yu, X; Zhao, J | 1 |
| Angiolillo, DJ; Becker, RC; Cannon, CP; Himmelmann, A; Huber, K; James, SK; Katus, HA; Lowenstern, A; Morais, J; Neely, M; Siegbahn, A; Steg, PG; Storey, RF; Sun, JL; Wallentin, L | 1 |
| Chen, Q; Geng, G; Han, W; Hao, Y; Hao, Z; Jia, K; Liu, H; Liu, L; Liu, Y; Wang, D; Zhou, Y | 1 |
| Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R | 1 |
| Bachelot-Loza, C; Belleville-Rolland, T; Gaussem, P; Godier, A; Helley, D; Martin, AC | 1 |
| Barrio, M; Do, B; Faucheron, A; Karoui, M; Rietveld, IB; Sadou Yayé, H; Secrétan, PH; Tilleul, P; Yagoubi, N | 1 |
| Albers, GW; Amarenco, P; Aunes, M; Bokelund-Singh, S; Denison, H; Easton, JD; Evans, SR; Held, P; Jahreskog, M; Johnston, SC; Jonasson, J; Minematsu, K; Molina, CA; Wang, Y; Wong, KSL | 1 |
| de Mast, Q; El Messaoudi, S; Gerretsen, J; Gomes, M; Kiers, D; Kox, M; Pickkers, P; Riksen, NP; Rongen, GA; van der Heijden, WA; van der Ven, AJ; van Ede, L | 1 |
| Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL | 1 |
| Budaj, A; Ramotowski, B; Żuk, A | 1 |
| Anuwatworn, A; Kumar, V; Petrasko, M; Stys, A; Yee, J | 1 |
| Giedraitiene, A; Jakstas, V; Kupstyte, N; Lesauskaite, V; Skipskis, V; Tatarunas, V; Zvikas, V | 1 |
| Bhatt, DL; Cannon, CP; Ellis, SG; Gropper, S; Harper, R; Hohnloser, SH; Januzzi, JL; Kimura, T; Kleine, E; Lip, GYH; Maeng, M; Manassie, J; Merkely, B; Nordaby, M; Oldgren, J; Steg, PG; Ten Berg, JM; Zeymer, U | 1 |
| Benfatto, G; Drago, F; Gozzo, L; Longo, L; Mansueto, S; Navarria, A; Pani, L; Salomone, S; Sottosanti, L | 1 |
| Bluestein, D; Consolo, F; Dimasi, A; Fiore, GB; Rasponi, M; Redaelli, A; Slepian, MJ | 1 |
| Brugaletta, S; Campo, G; Cortese, B; Geraci, S; Ielasi, A; Ishida, K; Latib, A; Nicolini, E; Poli, A; Rapetto, C; Scotto di Uccio, F; Secco, GG; Tespili, M; Varricchio, A; Vicinelli, P | 1 |
| Baos, S; Baumbach, A; Bowles, R; Culliford, L; Johnson, T; Mumford, A; Reeves, BC; Rogers, CA; Underwood, W | 1 |
| Cao, PG; Guo, DD; Quan, AJ; Shang, LL; Zhao, HY | 1 |
| de Man, FHAF; Doggen, CJM; Hartmann, M; Knottnerus, IL; Kok, MM; Linssen, GCM; Louwerenburg, JW; Löwik, MM; Stoel, MG; van der Heijden, LC; van Houwelingen, KG; von Birgelen, C; Zocca, P | 1 |
| Gremmel, T; Kopp, CW; Koppensteiner, R; Lang, IM; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C | 1 |
| Jia, P; Wang, XF; Ye, M; Zeng, YJ | 1 |
| Bryniarski, K; Hou, J; Hu, S; Jang, IK; Jia, H; Lee, H; Li, L; Liu, H; Ma, L; Sugiyama, T; Wang, C; Xing, L; Xu, M; Yamamoto, E; Yu, B; Zhang, S; Zhu, Y | 1 |
| Chen, X; Cheng, Z; Mei, J; Wang, X; Xu, Z; Zhao, Q; Zhu, Y | 1 |
| Benit, E; Chichareon, P; Dominici, M; Ferrario, M; Hamm, C; Heg, D; Huber, K; Janssens, L; Jüni, P; McFadden, EP; Möllmann, H; Moschovitis, A; Onuma, Y; Serruys, PW; Slagboom, T; Steg, PG; Valgimigli, M; van Es, GA; Van Geuns, RJ; van Meijeren, C; Vranckx, P; Windecker, S; Zurakowski, A | 1 |
| De Lorenzo, A; Dutra, M; Mattos, MA; Rey, HCV; Tibirica, E | 1 |
| Chen, L; Chi, G; Han, Y; Li, S; Liu, J; Lv, S; Shao, D; Wang, Y; Zhang, F; Zhang, J; Zhang, M | 1 |
| De Luca, G; Fierro, N; Gioscia, R; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Saghir Afifeh, AM; Suryapranata, H; Verdoia, M; Viglione, F | 1 |
| Chen, J; Li, X; Lv, Q; Wang, Z; Wu, H; Xue, Y | 1 |
| Dong, Z; Pan, L; Zhai, H; Zhang, B | 1 |
| Allahham, M; Atar, D; Birnbaum, Y; Lerman, A | 1 |
| Serebruany, V; Tanguay, JF | 1 |
| Cutlip, DE; Deliargyris, EN; Doros, G; Gibson, CM; Kroger, H; Lee, VT; Mack, MJ; Ohman, EM; Schneider, DJ; Sellke, FW; Thourani, VH | 1 |
| Friebel, J; Hassanein, A; Jakobs, K; Landmesser, U; Puccini, M; Rauch, C; Rauch, U | 1 |
| Han, X; He, M; Kong, Y; Li, Y; Liu, G; Ren, J; Shi, J; Yan, W; Zhang, Y; Zhao, Z | 1 |
| Chan, YH; Ganguly, A; Hwa, K; Li, Z; Ling, XB; Su, KJ; Tam, CF; Tse, HF; Wong, YK; Zhu, X | 1 |
| Aboalhasan, E; Abu-Dogosh, A; Abu-Salman, A; Alnsasra, H; Arbel, R; Azuri, J; Barrett, O; El Nasasra, A; Golan, YB; Hammerman, A; Tsaban, G; Weissberg, I; Westreich, R | 1 |
| Angiolillo, DJ; Been, L; Franchi, F; Galli, M; Rollini, F; Zenni, MM | 1 |
| Bender, L; Dorn, C; Franko, M; Franz, C; May, R; Minkenberg, J; Nikoubashman, O; Ridwan, H; Sichtermann, T; Stockero, A; Wiesmann, M | 1 |
| Cheung, SS; Hellsten, Y; Lundberg Slingsby, MH; Nørregaard, LB; Wickham, KA | 1 |
| Li, X; Lv, Q; Wang, Z; Xu, S; Yao, Y | 1 |
| Aldica, M; Anchidin, OI; Blendea, D; Moldovan, H; Molnar, A; Nemes, A; Pop, D; Rosianu, SH | 1 |
| Bai, Z; Jia, S; Li, Y; Liu, Y; Ma, H; Wang, H; Wang, J; Wang, T; Yan, R; Yang, L; Zhang, G; Zhang, X; Zhao, Y | 1 |
77 review(s) available for aspirin and adenosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Present status and prospects of platelet inhibitors].
Topics: Adenosine; Aspirin; Blood Platelets; Cyclic AMP; Cyclic GMP; Depression, Chemical; Drug Combinations; Drug Synergism; Humans; Phosphodiesterase Inhibitors; Platelet Aggregation; Prostaglandins E; Serotonin; Theophylline; Thrombosis | 1976 |
The role of platelets in glomerulonephritis.
Topics: Adenosine; Antidepressive Agents; Aspirin; Blood Platelets; Complement System Proteins; Endothelium; Glomerulonephritis; Hemostasis; Heparin; Histamine H1 Antagonists; Humans; Immunity; Immunoglobulins; Indomethacin; Kidney Diseases; Meclofenamic Acid; Mopidamol; Phagocytosis; Phenylbutazone; Platelet Aggregation; Prostaglandins; Pyrimidines; Sulfinpyrazone; Tranquilizing Agents; Warfarin | 1975 |
The pharmacology of platelet inhibition.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Anti-Inflammatory Agents; Anticoagulants; Aspirin; Blood Platelets; Citric Acid Cycle; Collagen; Cyclic AMP; Dipyridamole; Hexosephosphates; Histamine H1 Antagonists; Microscopy, Electron; Platelet Adhesiveness; Prostaglandins; Serotonin; Xanthines | 1972 |
Role of cyclic AMP in platelet function.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Biological Transport; Blood Platelets; Butyrates; Carbon Isotopes; Cell Aggregation; Collagen; Cyclic AMP; Epinephrine; Kaolin; Kinetics; Models, Biological; Phentolamine; Platelet Adhesiveness; Propranolol; Protein Kinases; Time Factors; Tritium | 1972 |
Research on haemostasis: some urgent questions.
Topics: Adenosine; Animals; Aspirin; Blood Coagulation; Blood Coagulation Factors; Blood Platelet Disorders; Blood Platelets; Blood Proteins; Erythrocyte Aggregation; Factor VIII; Fibrinolysis; Hemostasis; Humans | 1972 |
Haemostatic functions of platelets and their disorders.
Topics: Adenine; Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Afibrinogenemia; Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Blood Platelets; Carbon Isotopes; Hemostasis; Humans; Microscopy, Electron; Phosphates; Phosphorus Isotopes; Platelet Adhesiveness | 1972 |
Cellular and molecular mechanism(s) of coronary flow regulation by adenosine.
Topics: Adenine Nucleotides; Adenosine; Animals; Aspirin; Carotid Arteries; Coronary Circulation; Coronary Vessels; Cyclooxygenase Inhibitors; Hydrogen-Ion Concentration; Hypoxia; Indomethacin; Molecular Biology; Myocardium; Phosphates; Potassium; Prostaglandins; Receptors, Drug; Vasodilator Agents | 1980 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Dose-Response Relationship, Drug; Humans; Membrane Proteins; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2007 |
Clinical overview of promising nonthienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Pyridines; Receptors, Thrombin; Ticagrelor | 2008 |
Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; History, 20th Century; History, 21st Century; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y12; Stents; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2008 |
New antiplatelet drugs: beyond aspirin and clopidogrel.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Drug Design; Humans; Imines; Lactones; Naphthalenes; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Propionates; Purinergic P2 Receptor Antagonists; Pyridines; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
The role of antiplatelet therapy in the secondary prevention of coronary artery disease.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Secondary Prevention; Thiophenes; Thromboxane A2; Ticagrelor; Ticlopidine | 2010 |
Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Polymorphism, Genetic; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; Eptifibatide; Heart Diseases; Humans; Peptides; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Research Design; Research Support as Topic; Risk Factors; Sample Size; Thiophenes; Ticagrelor; Ticlopidine; United Kingdom | 2010 |
New antithrombotic agents--insights from clinical trials.
Topics: Adenosine; Anticoagulants; Aspirin; Clopidogrel; Coronary Thrombosis; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thromboembolism; Ticagrelor; Ticlopidine | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Resistance; Gastrointestinal Hemorrhage; Humans; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polymorphism, Genetic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Thiophenes; Ticagrelor; Ticlopidine; United States; United States Food and Drug Administration | 2010 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Disease Management; Drug Synergism; Drug Therapy, Combination; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Thiophenes; Ticagrelor; Ticlopidine | 2010 |
[Coronary heart disease - what is of importance after coronary intervention?].
Topics: Adenosine; Aftercare; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Disease; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Drug-Eluting Stents; Gastrointestinal Hemorrhage; Humans; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Proton Pump Inhibitors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
P2Y12 antagonists in acute coronary syndrome: in whom should they be started, and when?
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Humans; Integrin alpha2; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Quinazolinones; Receptors, Purinergic P2Y12; Sulfonamides; Tetrazoles; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Interactions; Humans; Platelet Activation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Risk Factors; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Heparin; Hirudins; Humans; Kidney Diseases; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Recombinant Proteins; Thiophenes; Ticagrelor; Ticlopidine; Uremia | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Echocardiography; Electrocardiography; Humans; Myocardial Infarction; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatment; Female; Humans; Male; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Quinazolinones; Sulfonamides; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Perioperative management of antiplatelet agents in patients undergoing cardiac surgery.
Topics: Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Artery Bypass; Humans; Perioperative Care; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Ticagrelor; Ticlopidine | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effectiveness Research; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Humans; Pharmacovigilance; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y; Risk Assessment; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Substitution; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Pharmacogenetics; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Product Surveillance, Postmarketing; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hemorrhage; Hemostasis; Humans; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Resistance; Genotype; Hemorrhage; Humans; Patient Selection; Percutaneous Coronary Intervention; Pharmacogenetics; Phenotype; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Precision Medicine; Predictive Value of Tests; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
Clopidogrel in coronary artery disease: update 2012.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2012 |
A critical overview on ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Double-Blind Method; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
[Novel agents for antithrombotic therapy in cardiology].
Topics: Adenosine; Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Coumarins; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Thrombolytic Therapy; Ticagrelor; Ticlopidine | 2012 |
Ticagrelor: the first novel reversible P2Y(12) inhibitor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2013 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.
Topics: Adenosine; Aspirin; Benzimidazoles; beta-Alanine; Cardiovascular Diseases; Clopidogrel; Dabigatran; Drug Interactions; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2013 |
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Secondary Prevention; Ticagrelor; Ticlopidine; Treatment Outcome; United States | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; Contraindications; Coronary Artery Bypass; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proton Pump Inhibitors; Secondary Prevention; Stents; Stroke; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2013 |
[Oral antiplatelet agents can still be used along with proton pump inhibitors in spite of drug interactions].
Topics: Adenosine; Administration, Oral; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Interactions; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Piperazines; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Thienopyridines; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Cardiovascular pharmacology core reviews: aspirin.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Primary Prevention; Secondary Prevention; Ticagrelor | 2013 |
[Thrombocyte aggregation inhibitors: what are the risks?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Risk Factors; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis.
Topics: Adenosine; Aged; Aspirin; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel; Cohort Studies; Data Interpretation, Statistical; Drug Therapy, Combination; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Population; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Secondary Prevention; Stroke; Thiophenes; Ticagrelor; Ticlopidine; Vascular Diseases | 2014 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Enoxaparin; Fondaparinux; Heparin; Hirudins; Humans; Morpholines; Peptide Fragments; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Thiophenes; Ticagrelor; Ticlopidine; Warfarin | 2014 |
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Multicenter Studies as Topic; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombolytic Therapy; Ticagrelor | 2014 |
Optimal aspirin dose in acute coronary syndromes: an emerging consensus.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thiophenes; Ticagrelor | 2014 |
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Intermittent Claudication; Ischemia; Lower Extremity; Meta-Analysis as Topic; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Primary Prevention; Review Literature as Topic; Secondary Prevention; Stroke; Tetrazoles; Thrombosis; Ticagrelor; Ticlopidine | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Early Medical Intervention; General Practice; Guideline Adherence; Humans; Male; Middle Aged; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Quality of Health Care; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Eptifibatide; Fondaparinux; Heparin; Hirudins; Humans; Lactones; Peptide Fragments; Peptides; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Polysaccharides; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Pyridines; Receptors, Thrombin; Recombinant Proteins; Thiophenes; Ticagrelor; Tirofiban; Tyrosine; Warfarin | 2014 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Intraoperative Care; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Thiophenes; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Ticagrelor, prasugrel, or clopidogrel in ST-segment elevation myocardial infarction: which one to choose?
Topics: Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Spontaneous coronary artery dissection: the management dilemma continues.
Topics: Adenosine; Adult; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Carbazoles; Carvedilol; Coronary Angiography; Coronary Vessel Anomalies; Diagnosis, Differential; Echocardiography; Electrocardiography; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Propanolamines; Purinergic P2Y Receptor Antagonists; Ticagrelor; Vascular Diseases | 2015 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptor, PAR-1; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2015 |
Solid cancers after antiplatelet therapy: Confirmations, controversies, and challenges.
Topics: Adenosine; Animals; Anticarcinogenic Agents; Aspirin; Blood Platelets; Carcinogenicity Tests; Clopidogrel; Colonic Neoplasms; Drug Therapy, Combination; Female; Humans; Lactones; Male; Mice; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasms; Neoplasms, Experimental; Neoplastic Cells, Circulating; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Randomized Controlled Trials as Topic; Rivaroxaban; Sex Factors; Species Specificity; Ticagrelor; Ticlopidine; Time Factors | 2015 |
Antiplatelet Agents in Cardiology: A Report on Aspirin, Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine; Transcatheter Aortic Valve Replacement | 2016 |
Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Recurrence; Risk Assessment; Risk Factors; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Proton Pump Inhibitors in Cardiovascular Disease: Drug Interactions with Antiplatelet Drugs.
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Administration Schedule; Drug Dosage Calculations; Drug Interactions; Esomeprazole; Gastrointestinal Hemorrhage; Gene Expression; Humans; Hydrogen-Ion Concentration; Peptic Ulcer; Prasugrel Hydrochloride; Proton Pump Inhibitors; Purinergic Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Ticlopidine | 2017 |
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; Factor Xa Inhibitors; Hemorrhage; History, 20th Century; History, 21st Century; History, Ancient; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Ticagrelor; Ticlopidine | 2016 |
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Disease Management; Humans; Nurse Practitioners; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet treatments: recent evidence from randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Atherosclerosis; Blood Platelets; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Ticlopidine | 2017 |
[Management of the bleeding risk associated with antiplatelet agents].
Topics: Adenosine; Aspirin; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
[Antiplatelet agents and transfusion].
Topics: Adenosine; Antidotes; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Platelet Transfusion; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine | 2017 |
Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin: A Systematic Review and Meta-Analysis.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Proportional Hazards Models; Recurrence; Secondary Prevention; Stroke; Ticagrelor; Ticlopidine; Treatment Failure | 2017 |
A Primer on Bleeding Risk and Management Strategies of Newer Oral Anti Platelet Agents in Cardiovascular Disease.
Topics: Adenosine; Administration, Oral; Aspirin; Cardiovascular Diseases; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Why Not Dipyridamole: a Review of Current Guidelines and Re-evaluation of Utility in the Modern Era.
Topics: Adenosine; Animals; Aspirin; Dipyridamole; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rats; Vasodilator Agents | 2022 |
64 trial(s) available for aspirin and adenosine
| Article | Year |
|---|---|
European Stroke Prevention Study-2 results: serendipitous demonstration of neuroprotection induced by endogenous adenosine accumulation?
Topics: Adenosine; Aspirin; Blood-Brain Barrier; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; Humans; Neuroprotective Agents; Placebos; Platelet Aggregation Inhibitors | 1998 |
Role of adenosine and nitric oxide on the mechanisms of action of dipyridamole.
Topics: Acetylcholine; Adenosine; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Flow Velocity; Cardiovascular System; Cross-Over Studies; Cyclic GMP; Dipyridamole; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Models, Biological; Nitric Oxide; Nitroprusside; Phosphoric Diester Hydrolases; Time Factors; Vasodilator Agents | 2005 |
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin.
Topics: Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Bleeding Time; Clopidogrel; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Postmenopause; Ticagrelor; Ticlopidine | 2006 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Ticagrelor; Ticlopidine | 2007 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Retrospective Studies; Surveys and Questionnaires; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Phosphoproteins; Phosphorylation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Treatment Outcome | 2009 |
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogrel; Double-Blind Method; Female; Humans; Interleukin-6; Male; Middle Aged; Peroxidase; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Dyspnea; Female; Heart; Humans; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine | 2010 |
First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
Topics: Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Double-Blind Method; Genotype; Humans; Male; Middle Aged; Pharmacokinetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Female; Global Health; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Stroke; Ticagrelor; Ticlopidine; United States | 2011 |
The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies.
Topics: Adenosine; Administration, Oral; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine; Treatment Outcome | 2011 |
Rationale and design of the on-treatment PLAtelet Reactivity-Guided Therapy Modification FOR ST-Segment Elevation Myocardial Infarction (PLATFORM) randomized trial.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; Diagnostic Imaging; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Drugs, Generic; Health Care Costs; Hospitalization; Humans; Markov Chains; Myocardial Reperfusion; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Switzerland; Ticagrelor; Ticlopidine | 2013 |
Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Cytochrome P-450 CYP2C19; Female; Humans; Male; Pilot Projects; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Point-of-Care Systems; Prasugrel Hydrochloride; Thiophenes; Ticagrelor | 2014 |
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Premedication; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Time Factors; Treatment Outcome | 2014 |
Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Young Adult | 2014 |
Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin.
Topics: Adenosine; Adult; Antithrombins; Aspirin; Blood Coagulation; Clopidogrel; Cross-Over Studies; Drug Synergism; Female; Healthy Volunteers; Hirudins; Humans; Male; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recombinant Proteins; Thrombelastography; Ticagrelor; Ticlopidine | 2014 |
Antithrombotic triple therapy and coagulation activation at the site of thrombus formation: a randomized trial in healthy subjects.
Topics: Adenosine; Administration, Oral; Adult; Anticoagulants; Antithrombin III; Aspirin; Austria; Benzimidazoles; beta-Alanine; beta-Thromboglobulin; Biomarkers; Blood Coagulation; Blood Platelets; Dabigatran; Drug Therapy, Combination; Fibrinolytic Agents; Healthy Volunteers; Humans; International Normalized Ratio; Male; Morpholines; Peptide Fragments; Peptide Hydrolases; Phenprocoumon; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Prothrombin; Rivaroxaban; Thiophenes; Thrombin; Thrombosis; Ticagrelor; Young Adult | 2014 |
Rationale and design of MANJUSRI trial: a randomized, open-label, active-controlled multicenter study to evaluate the safety of combined therapy with ticagrelor and warfarin in AF subjects after PCI-eS.
Topics: Adenosine; Adolescent; Adult; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Prospective Studies; Research Design; Ticagrelor; Ticlopidine; Warfarin; Young Adult | 2015 |
Platelet reactivity after receiving clopidogrel compared with ticagrelor in patients with kidney failure treated with hemodialysis: a randomized crossover study.
Topics: Adenosine; Adult; Aspirin; Clopidogrel; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Renal Dialysis; Single-Blind Method; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Long-term use of ticagrelor in patients with prior myocardial infarction.
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Secondary Prevention; Ticagrelor | 2015 |
Comparison of Prasugrel and Ticagrelor Antiplatelet Effects in Korean Patients Presenting With ST-Segment Elevation Myocardial Infarction.
Topics: Adenosine; Adult; Aged; Asian People; Aspirin; Cardiac Catheterization; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Complications; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Sample Size; Thrombophilia; Thrombosis; Ticagrelor | 2015 |
Rationale and design of the RT-AF study: Combination of rivaroxaban and ticagrelor in patients with atrial fibrillation and coronary artery disease undergoing percutaneous coronary intervention.
Topics: Adenosine; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Hemorrhage; Humans; Percutaneous Coronary Intervention; Research Design; Rivaroxaban; Ticagrelor; Ticlopidine; Warfarin | 2015 |
Exploration of efficacy and bleeding with combined phosphoinositide 3-kinase β inhibition and aspirin in man.
Topics: Adenosine; Adult; Animals; Aspirin; Blood Platelets; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Dogs; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Male; Models, Animal; ortho-Aminobenzoates; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Protein Kinase Inhibitors; Purinergic P2Y Receptor Antagonists; Pyrimidinones; Receptors, Purinergic P2Y12; Sweden; Ticagrelor; Young Adult | 2015 |
Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Female; Humans; Male; Middle Aged; Pilot Projects; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design.
Topics: Adenosine; Aspirin; Double-Blind Method; Fibrinolytic Agents; Follow-Up Studies; Humans; Internationality; Ischemic Attack, Transient; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Research Design; Ticagrelor; Treatment Outcome | 2015 |
Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2015 |
Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Purinergic P2Y Receptor Antagonists; Republic of Korea; Ticagrelor; Time Factors; Tirofiban; Treatment Outcome; Tyrosine | 2016 |
Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Drug Combinations; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Sirolimus; Ticagrelor; Time; Treatment Outcome; Young Adult | 2016 |
Effects of P2Y12 receptor inhibition with or without aspirin on hemostatic system activation: a randomized trial in healthy subjects.
Topics: Adenosine; Adolescent; Adult; Area Under Curve; Aspirin; Austria; beta-Thromboglobulin; Biomarkers; Bleeding Time; Blood Platelets; Clopidogrel; Double-Blind Method; Healthy Volunteers; Hemostasis; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prothrombin; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; ROC Curve; Ticagrelor; Ticlopidine; Time Factors; Young Adult | 2016 |
Ticagrelor and aspirin for the prevention of cardiovascular events after coronary artery bypass graft surgery.
Topics: Adenosine; Aged; Aspirin; British Columbia; Chi-Square Distribution; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Early Termination of Clinical Trials; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation Inhibitors; Prospective Studies; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Ticagrelor; Ticlopidine; Treatment Outcome; Young Adult | 2016 |
Pharmacodynamic Effects of Switching From Prasugrel to Ticagrelor: Results of the Prospective, Randomized SWAP-3 Study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aspirin; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Female; Florida; Humans; Male; Microfilament Proteins; Middle Aged; Percutaneous Coronary Intervention; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticagrelor; Time Factors; Treatment Outcome | 2016 |
Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
Topics: Adenosine; Aged; Area Under Curve; Asian People; Aspirin; Blood Platelets; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease.
Topics: Adenosine; Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hemorrhage; Humans; Ischemia; Lower Extremity; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Stroke; Ticagrelor; Vascular Grafting | 2016 |
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Extremities; Female; Follow-Up Studies; Humans; Male; Middle Aged; Peripheral Arterial Disease; Prospective Studies; Severity of Illness Index; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Humans; Japan; Ticagrelor; Ticlopidine; Treatment Outcome; United States; White People | 2016 |
Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack.
Topics: Adenosine; Aged; Aspirin; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Kaplan-Meier Estimate; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Graft Occlusion, Vascular; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Peptides; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Tirofiban; Tyrosine | 2016 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Graft Occlusion, Vascular; Hemorrhage; Humans; Mortality; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stroke; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Prevention of Stroke with Ticagrelor in Patients with Prior Myocardial Infarction: Insights from PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Throm
Topics: Adenosine; Aged; Aspirin; Coronary Artery Disease; Female; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Secondary Prevention; Stroke; Ticagrelor | 2016 |
A randomized, parallel group, double-blind study of ticagrelor compared with aspirin for prevention of vascular events in patients undergoing coronary artery bypass graft operation: Rationale and design of the Ticagrelor in CABG (TiCAB) trial: An Investig
Topics: Adenosine; Aged; Aspirin; Cardiovascular Diseases; Coronary Artery Bypass; Coronary Artery Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2016 |
Safety of Preoperative Use of Ticagrelor With or Without Aspirin Compared With Aspirin Alone in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Grafting.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Coronary Artery Bypass; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor | 2016 |
Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes).
Topics: Adenosine; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Aspirin; Cohort Studies; Double-Blind Method; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Middle Aged; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Coronary Restenosis; Double-Blind Method; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Adjustment; Ticagrelor; Treatment Outcome | 2016 |
Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial.
Topics: Adenosine; Adult; Aged; Aspirin; Atherosclerosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fibrinolytic Agents; Humans; International Cooperation; Ischemic Attack, Transient; Male; Middle Aged; Proportional Hazards Models; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; Growth Differentiation Factor 15; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Risk Assessment; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Tablets; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI.
Topics: Adenosine; Aged; Alanine Transaminase; Aspartate Aminotransferases; Aspirin; Blood Glucose; Cardiac Output; China; Creatine Kinase; Creatine Kinase, MB Form; Creatinine; Diabetes Mellitus, Type 2; Echocardiography; Female; Glycated Hemoglobin; Heart Atria; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Stroke Volume; Ticagrelor; Treatment Outcome; Trimetazidine; Troponin I; Urea; Vasodilator Agents | 2017 |
Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Clopidogrel; Female; Humans; Male; Middle Aged; P-Selectin; Platelet Aggregation Inhibitors; Platelet Count; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors | 2017 |
Short-term efficacy and safety of three different antiplatelet regimens in diabetic patients treated with primary percutaneous coronary intervention: a randomised study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Diabetic Cardiomyopathies; Double-Blind Method; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Patient Safety; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine | 2017 |
A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Topics: Adenosine; Administration, Intravenous; Adolescent; Adult; Aspirin; Cells, Cultured; Clopidogrel; Cytokines; Drug Therapy, Combination; Endotoxemia; Endotoxins; Healthy Volunteers; Humans; Inflammation; Inflammation Mediators; Male; Netherlands; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Young Adult | 2017 |
Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source.
Topics: Adenosine; Aged; Aortic Diseases; Aspirin; Atherosclerosis; Carotid Stenosis; Female; Humans; Intracranial Embolism; Ischemic Attack, Transient; Male; Middle Aged; Mortality; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
Topics: Adenosine; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Dabigatran; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk; Ticagrelor; Ticlopidine; Warfarin | 2017 |
Platelet inhibition during ticagrelor monotherapy versus ticagrelor plus aspirin in patients with coronary artery disease (TEMPLATE study): study protocol for a randomised controlled trial.
Topics: Adenosine; Aspirin; Clinical Protocols; Coronary Artery Disease; Drug Therapy, Combination; England; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Research Design; Risk Factors; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Comparison of pharmacodynamic effects of ticagrelor vs prasugrel in type 2 diabetes mellitus patients with coronary heart disease.
Topics: Adenosine; Aged; Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thrombosis; Ticagrelor; Time Factors | 2018 |
Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial.
Topics: Adenosine; Adult; Aged; Aspirin; Coronary Artery Bypass; Coronary Restenosis; Drug Therapy, Combination; Elective Surgical Procedures; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Saphenous Vein; Ticagrelor; Vascular Patency | 2018 |
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-la
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Intention to Treat Analysis; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2018 |
Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelo
Topics: Adenosine; Aspirin; Ataxia Telangiectasia Mutated Proteins; Fibrinolytic Agents; Humans; Platelet Aggregation Inhibitors; Postoperative Hemorrhage; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study).
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Cross-Over Studies; Epinephrine; Fibrinolytic Agents; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2022 |
Multi-Omics Signatures Link to Ticagrelor Effects on Vascular Function in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Epidermal Growth Factor; Humans; Interleukin-6; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Treatment Outcome | 2022 |
Impact of diabetes mellitus on the pharmacodynamic effects of prasugrel and ticagrelor after switching from clopidogrel in patients with coronary artery disease.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor | 2022 |
191 other study(ies) available for aspirin and adenosine
| Article | Year |
|---|---|
Novel arylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-dioxides as inhibitors of platelet aggregation. 1. Synthesis and pharmacological evaluation.
Topics: Animals; Cyclic S-Oxides; Humans; In Vitro Techniques; Male; Platelet Aggregation Inhibitors; Rabbits; Rats; Rats, Wistar; Structure-Activity Relationship; Thiadiazines | 1999 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Interaction of salicylic acid with adenosine and adenosine triphosphate. Potential mechanism of intensifying acetylsalicylic acid-induced GI blood loss.
Topics: Adenosine; Adenosine Triphosphate; Aspirin; Chemical Phenomena; Chemistry; Gastrointestinal Hemorrhage; Hydrogen-Ion Concentration; Salicylates; Surface Tension | 1976 |
Platelet retention in glass bead columns: its mechanism and the effect of plasma proteins.
Topics: Adenosine; Adenosine Monophosphate; Animals; Aspirin; Cattle; Female; Fibrinogen; gamma-Globulins; Heparin; Humans; In Vitro Techniques; Male; Platelet Adhesiveness; Serum Albumin | 1976 |
[Interactions of platelet inhibitors].
Topics: Adenosine; Aspirin; Dipyridamole; Drug Interactions; Guanylate Cyclase; Humans; Nucleoside-Diphosphate Kinase; Oxygenases; Papaverine; Phospholipases A; Phosphoric Diester Hydrolases; Platelet Aggregation; Thromboxane-A Synthase | 1979 |
In vitro evaluation of inhibitors of platelet release and aggregation.
Topics: Adenosine; Adenosine Diphosphate; Anti-Inflammatory Agents; Antilymphocyte Serum; Aspirin; Blood Platelets; Collagen; Depression, Chemical; Dextrans; Dipyridamole; Epinephrine; Hematology; Humans; Molecular Weight; Phosphoric Monoester Hydrolases; Platelet Adhesiveness; Platelet Aggregation; Propionates; Prostaglandins E; Serotonin; Sulfinpyrazone; T-Lymphocytes | 1975 |
Platelet release and aggregation induced by antithymocyte globulin. In vitro effect of inhibitors.
Topics: Adenosine; Antilymphocyte Serum; Apyrase; Aspirin; Blood Platelets; Dipyridamole; Flurbiprofen; Humans; Phosphoric Monoester Hydrolases; Platelet Aggregation; Propionates; Prostaglandins E; Sulfinpyrazone; T-Lymphocytes | 1975 |
Platelet aggregometry and anti-platelet isoantibodies.
Topics: Adenosine; Adenosine Diphosphate; Adenylate Kinase; Animals; Antilymphocyte Serum; Aspirin; Blood Platelets; Bucladesine; Heparin; HLA Antigens; Immune Sera; Isoantibodies; Platelet Aggregation; Platelet Factor 3; Platelet Factor 4; Prostaglandins E; Snake Venoms; Thrombin | 1975 |
Aggregation of gel-filtered guinea-pig platelets by lipoproteins.
Topics: Adenosine; Adenosine Diphosphate; Animals; Apyrase; Aspirin; Chromatography, Gel; Dipyridamole; Guinea Pigs; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Platelet Aggregation; Prostaglandins E | 1979 |
Interactions of poly (L-lysine) with human platelets. Correlation of binding with induction of platelet aggregation.
Topics: Adenosine; Aspirin; Binding Sites; Binding, Competitive; Blood Platelets; Cell Membrane; Cyclic AMP; Edetic Acid; Formaldehyde; Humans; Iodine Radioisotopes; Peptides; Platelet Aggregation; Polylysine; Prostaglandins E | 1979 |
Effect of platelet activation on the platelet surface sialic acid.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Cell Membrane; Collagen; Epinephrine; Humans; Neuraminidase; Sialic Acids; Thrombin | 1979 |
Effect of 1-methyl-2-mercapto-5-(3-pyridyl)-imidazole (KC-6141) on rabbit platelet aggregation in vitro and rat platelet retention.
Topics: Adenosine; Animals; Aspirin; Dipyridamole; Glass; Imidazoles; Platelet Adhesiveness; Platelet Aggregation; Pyridines; Rabbits; Rats | 1978 |
Spontaneous platelet aggregation in cerebrovascular disease.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aged; Aspirin; Blindness; Brain Diseases; Female; Humans; Ischemic Attack, Transient; Male; Middle Aged; Paresthesia; Phentolamine; Platelet Aggregation | 1978 |
Ultrastructural studies on the surface coat of human platelet aggregated by polylysine and dextran.
Topics: Adenosine; Aspirin; Blood Platelets; Cell Membrane; Dextrans; Heparin; Humans; Macromolecular Substances; Peptides; Platelet Aggregation; Polylysine; Prostaglandins E; Serotonin | 1978 |
Platelet interaction with bacteria. IV. Stimulation of the release reaction.
Topics: Adenosine; Aspirin; Bacteria; Blood Platelets; Carbon Radioisotopes; Collagen; Cyanides; Deoxyglucose; Edetic Acid; Epinephrine; Humans; In Vitro Techniques; Oligomycins; Phosphoenolpyruvate; Platelet Aggregation; Polylysine; Prostaglandins E; Pyruvate Kinase; Serotonin; Staphylococcus aureus; Thrombin | 1975 |
Spontaneous platelet aggregation in arterial insufficiency: mechanisms and implications.
Topics: Adenosine; Adult; Aged; Angina Pectoris; Apyrase; Arterial Occlusive Diseases; Aspirin; Coronary Disease; Dipyridamole; Heparin; Hirudins; Humans; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Platelet Aggregation; Prostaglandins E | 1976 |
Rat platelet aggregation by ATP. Aggregometrical and ultrastructural comparison with aggregations induced by ADP and collagen.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Apyrase; Aspirin; Blood Platelets; Collagen; Female; Humans; Male; Platelet Aggregation; Rats | 1976 |
Inhibition of human and animal platelet adhesiveness to glass bead columns by adenosine, dipyridamole, chlorpromazine and acetylsalicylic acid.
Topics: Adenosine; Animals; Aspirin; Blood Flow Velocity; Chlorpromazine; Dipyridamole; Glass; Guinea Pigs; Heparin; Humans; In Vitro Techniques; Platelet Adhesiveness; Rabbits; Species Specificity | 1976 |
Effect of adenosine and inosine administration on platelet function in rabbits.
Topics: Adenosine; Animals; Aspirin; Blood Platelets; Cyclic AMP; Female; Inosine; Male; Platelet Adhesiveness; Platelet Aggregation; Platelet Function Tests; Rabbits | 1990 |
Red blood cells mediate spontaneous aggregation of platelets in whole blood.
Topics: 2-Chloroadenosine; Adenosine; Adult; Aged; Aspirin; Epoprostenol; Erythrocytes; Humans; Iloprost; In Vitro Techniques; Middle Aged; Platelet Aggregation; Platelet Count; Sulfonamides; Thrombosis | 1987 |
Effects of exogenous vasoconstrictors on coronary vascular resistance and prostacyclin production of the quiescent heart: the inhibitory effect of aspirin.
Topics: Adenosine; Animals; Aspirin; Coronary Vessels; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Epoprostenol; Heart; Male; Rats; Rats, Inbred Strains; Tranylcypromine; Vascular Resistance; Vasoconstrictor Agents | 1989 |
Effect of the thromboxane A2 receptor antagonist SQ 30,741 on ultimate myocardial infarct size, reperfusion injury and coronary flow reserve.
Topics: Adenosine; Animals; Aspirin; Coronary Circulation; Dogs; Female; Male; Myocardial Infarction; Receptors, Prostaglandin; Receptors, Thromboxane; Reperfusion Injury; Thromboxane A2 | 1989 |
Synergistic actions of paf-acether and sodium arachidonate in human platelet aggregation. 2. Unexpected results after aspirin intake.
Topics: 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; Adenosine; Administration, Oral; Adult; Apyrase; Arachidonic Acids; Aspirin; Catechols; Drug Synergism; Epoprostenol; Humans; Indomethacin; Masoprocol; Platelet Activating Factor; Platelet Aggregation; Pyrazoles; Thromboxane B2; Time Factors; Umbelliferones | 1986 |
Increased vascular resistance due to a reduction in red cell deformability in the isolated hind limb of swine.
Topics: Adenosine; Animals; Aspirin; Blood Transfusion; Blood Viscosity; Erythrocyte Deformability; Erythrocyte Transfusion; Female; Formaldehyde; Hindlimb; Injections, Intra-Arterial; Male; Mercury; Microcirculation; Phentolamine; Regional Blood Flow; Swine; Vascular Resistance; Vasodilation | 1988 |
Heparin-induced thrombocytopenia platelet aggregation studies in the presence of heparin fractions or semi-synthetic analogues of various molecular weights and anticoagulant activities.
Topics: Adenosine; Aged; Aspirin; Epoprostenol; Heparin; Humans; In Vitro Techniques; Male; Molecular Weight; Platelet Aggregation; Prostaglandin D2; Prostaglandins D; Thrombocytopenia | 1986 |
Effects of vagotomy and drugs on the ventricular fibrillation threshold of normal and ischemic hearts in the anesthetized rat.
Topics: Adenosine; Anesthesia; Animals; Aspirin; Blood Pressure; Bretylium Compounds; Coronary Disease; Heart Rate; Lidocaine; Male; Nitroprusside; Rats; Vagotomy; Ventricular Fibrillation | 1985 |
[Effect of adenosine, acetylsalicylic acid, phenylbutazone and papaverine on platelet aggregation].
Topics: Adenine Nucleotides; Adenosine; Animals; Aspirin; Blood Coagulation Tests; Blood Platelets; Densitometry; Humans; Papaverine; Phenylbutazone; Platelet Adhesiveness; Prothrombin; Rabbits | 1971 |
Arachidonic acid-induced human platelet aggregation and prostaglandin formation.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arachidonic Acids; Aspirin; Blood Platelets; Carbon Radioisotopes; Chromatography, Thin Layer; Collagen; Depression, Chemical; Dose-Response Relationship, Drug; Epinephrine; Guinea Pigs; Humans; Hydrogen-Ion Concentration; Naphthols; Photometry; Platelet Adhesiveness; Prostaglandin Antagonists; Prostaglandins; Rabbits; Radioimmunoassay; Stimulation, Chemical | 1973 |
Human platelet clumping by bovine fibrinogen.
Topics: Adenosine; Adenosine Diphosphate; Afibrinogenemia; Animals; Aspirin; Blood Platelets; Cattle; Chromatography, Gel; Depression, Chemical; Edetic Acid; Fibrinogen; Fibrinolysin; Hot Temperature; Humans; Male; Plasma; Platelet Adhesiveness | 1972 |
Methods for the separation of platelets from plasma. A comparison of functional and morphological integrity.
Topics: Adenosine; Adenosine Diphosphate; Adenosine Triphosphate; Aspirin; Blood Coagulation Factors; Blood Platelets; Cell Separation; Centrifugation, Density Gradient; Chromatography, Gel; Collagen; Humans; Luminescent Measurements; Methods; Microscopy, Electron; Phosphoric Monoester Hydrolases; Platelet Adhesiveness; Prostaglandins; Serum Albumin, Bovine; Venoms | 1974 |
Effects of the lonophore A23187 on blood platelets I. Influence on aggregation and secretion.
Topics: Adenosine; Anti-Bacterial Agents; Aspirin; Atropine; Blood Platelets; Bucladesine; Calcium; Carbon Radioisotopes; Carboxylic Acids; Cyclic AMP; Cytoplasm; Deoxyglucose; Dimethyl Sulfoxide; Edetic Acid; Ethanol; Ethylmaleimide; Humans; L-Lactate Dehydrogenase; Lanthanum; Platelet Adhesiveness; Platelet Aggregation; Prostaglandins; Serotonin; Theophylline | 1974 |
An endoperoxide aggregator (Lass), formed in platelets in response to thrombotic stimuli: purification, identification and unique biological significance.
Topics: Adenosine; Animals; Aorta; Arachidonic Acids; Aspirin; Blood Platelets; Calcium; Collagen; Epinephrine; Fatty Acids, Unsaturated; Humans; Male; Mice; Muscle, Smooth; Peroxides; Platelet Adhesiveness; Platelet Aggregation; Prostaglandins E; Rabbits; Rats; Serotonin; Thrombin | 1974 |
Interaction of salicylic acid with adenosine and adenosine triphosphate: potential mechanism of intensifying aspirin-induced GI blood loss.
Topics: Adenosine; Adenosine Triphosphate; Aspirin; Chemical Phenomena; Chemistry; Drug Interactions; Gastrointestinal Hemorrhage; Hydrogen-Ion Concentration; Kinetics; Platelet Aggregation; Salicylates; Spectrophotometry, Ultraviolet | 1974 |
On the mechanism of platelet aggregation induced by heparin, protamine and polybrene.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Cell Membrane; Edetic Acid; Heparin; Heparin Antagonists; In Vitro Techniques; Platelet Adhesiveness; Polymers; Protamines | 1972 |
Inhibition of platelet aggregation by drugs.
Topics: Adenosine; Adenosine Diphosphate; Animals; Aspirin; Blood Cell Count; Blood Coagulation; Blood Platelets; Collagen; Densitometry; Depression, Chemical; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Injections, Intravenous; Methods; Muscle, Smooth; Papaverine; Phenylbutazone; Platelet Adhesiveness; Rabbits; Temperature; Thrombin; Vasodilator Agents | 1972 |
Leucocytes and thrombosis. 3. Effect on white cell behaviour of substances which induce or inhibit platelet aggregation.
Topics: Adenosine; Aspirin; Catecholamines; Collagen; Dipyridamole; Epinephrine; Isoproterenol; Leukocytes; Norepinephrine; Serotonin; Tendons; Thrombosis | 1973 |
The measurement of intravascular aggregation by continuous platelet counting.
Topics: Adenosine; Adenosine Diphosphate; Animals; Aspirin; Blood Cell Count; Blood Platelets; Catheterization; Citrates; Dipyridamole; Dogs; Guinea Pigs; Methysergide; Platelet Adhesiveness; Prostaglandins; Rabbits; Serotonin; Serotonin Antagonists | 1973 |
Effect of 4,5-diphenyl-2-bis-(2-hydroxyethyl)aminoxazol (ditazol) on platelet aggregation, adhesiveness and bleeding time.
Topics: Adenosine; Adenosine Diphosphate; Adult; Analysis of Variance; Animals; Anti-Inflammatory Agents; Aspirin; Blood Coagulation; Collagen; Dipyridamole; Drug Interactions; Epinephrine; Ethanol; Ethanolamines; Humans; Male; Mice; Middle Aged; Oxazoles; Phenylbutazone; Platelet Adhesiveness; Rabbits; Time Factors | 1973 |
Inhibition of platelet-induced thrombus formation.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Diseases; Dipyridamole; Epinephrine; Glomerulonephritis; Heart Valve Prosthesis; Humans; Hypertension, Malignant; Ischemia; Myocardial Infarction; Platelet Adhesiveness; Postoperative Complications; Prostaglandins; Pyrimidines; Thromboembolism; Thrombophlebitis; Thrombosis; Xanthines | 1974 |
Aggregation of human platelets by commercial preparations of bovine and porcine antihaemophilic globulin.
Topics: Adenosine; Animals; Aspirin; Blood Cell Count; Cattle; Densitometry; Factor VIII; Fibrinogen; Goats; Hemoglobinometry; Hemophilia A; Heparin; Horses; Humans; In Vitro Techniques; Platelet Adhesiveness; Sheep; Spectrum Analysis; Swine; Temperature; Thrombocytopenia; Trichloroacetic Acid | 1972 |
Comparison of the effects of drugs on the aggregation of hamster platelets in vivo and in vitro.
Topics: Adenosine; Adenosine Diphosphate; Animals; Aspirin; Blood Volume; Carbon Isotopes; Cheek; Cricetinae; Desipramine; Imipramine; In Vitro Techniques; Iontophoresis; Microcirculation; Platelet Adhesiveness; Sodium Salicylate; Tritium | 1971 |
Dissociation between platelet factor 3 availability and platelet aggregation.
Topics: Absorption; Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Collagen; Glycolysis; Humans; Indomethacin; Oxidative Phosphorylation; Platelet Adhesiveness; Purpura, Thrombocytopenic; Spectrum Analysis; Thromboplastin; Time Factors | 1971 |
Studies of human plate alpha-granule release in vivo.
Topics: Adenosine; Adult; Anticoagulants; Aspirin; beta-Thromboglobulin; Blood Platelets; Blood Specimen Collection; Bucladesine; Centrifugation; Cytoplasmic Granules; Female; Humans; Male; Middle Aged; Platelet Count; Platelet Factor 4; Prostaglandins E; Temperature; Theophylline; Thrombocytopenia; Time Factors | 1981 |
The aggregation of human platelets by ascitic fluid: a possible mechanism for disseminated intravascular coagulation complicating LeVeen shunts.
Topics: Adenosine; Adult; Aged; Ascitic Fluid; Aspirin; Disseminated Intravascular Coagulation; Edetic Acid; Female; Humans; Hydroxyproline; Male; Microbial Collagenase; Middle Aged; Peritoneovenous Shunt; Platelet Aggregation; Vascular Surgical Procedures | 1981 |
Effects of drugs on adhesion of human platelets.
Topics: Adenosine; Aspirin; Chlorpromazine; Cyclic IMP; Dipyridamole; Glass; Humans; Platelet Adhesiveness | 1981 |
Responses to adenine nucleotides and related compounds of isolated dog cerebral, coronary and mesenteric arteries.
Topics: Adenosine; Adenosine Triphosphate; Aminophylline; Animals; Aspirin; Cerebrovascular Circulation; Coronary Circulation; Cyclic AMP; Dogs; Dose-Response Relationship, Drug; Female; Male; Mesenteric Arteries; Structure-Activity Relationship | 1982 |
Adenosine-mediated inhibition of platelet aggregation by acadesine. A novel antithrombotic mechanism in vitro and in vivo.
Topics: Adenosine; Adenosine Deaminase; Adenosine Kinase; Aminoimidazole Carboxamide; Animals; Aspirin; Blood Physiological Phenomena; Coronary Thrombosis; Coronary Vessels; Dipyridamole; Disease Models, Animal; Dogs; Erythrocytes; Humans; Male; Plasma; Platelet Aggregation; Purinergic P1 Receptor Antagonists; Regional Blood Flow; Ribonucleosides; Theophylline; Tubercidin | 1994 |
Beneficial effect of aspirin and heparin in three-day dog kidney preservation.
Topics: Adenosine; Allopurinol; Animals; Aspirin; Chondroitin Sulfates; Creatinine; Dogs; Female; Glutathione; Heparin; Insulin; Kidney; Kidney Function Tests; Kidney Transplantation; Organ Preservation; Organ Preservation Solutions; Raffinose | 1993 |
[Potentiation of the antiplatelet effect of dipyridamole and aspirin by erythrocytes. Study under flow conditions].
Topics: Adenosine; Animals; Aorta, Abdominal; Aspirin; Dipyridamole; Drug Synergism; Erythrocytes; Humans; Muscle, Smooth, Vascular; Perfusion; Platelet Aggregation; Rabbits | 1993 |
Coordinated inhibition of actin-induced platelet aggregation by plasma gelsolin and vitamin D-binding protein.
Topics: Actins; Adenosine; Adenosine Diphosphate; Animals; Apyrase; Aspirin; Dose-Response Relationship, Drug; Gelsolin; Humans; Kinetics; Platelet Aggregation; Platelet Aggregation Inhibitors; Rabbits; Vitamin D-Binding Protein | 1993 |
Presence of pituitary adenylate cyclase-activating polypeptide 38-immuno-like material in the brain and ovary of the female crested newt, Triturus carnifex: its involvement in the ovarian synthesis of prostaglandins and steroids.
Topics: Adenosine; Adenylyl Cyclase Inhibitors; Animals; Aspirin; Brain; Brain Chemistry; Chromatography, High Pressure Liquid; Corticosterone; Cyclooxygenase Inhibitors; Dinoprostone; Female; Neuropeptides; Neurotransmitter Agents; Organ Culture Techniques; Ovary; p-Methoxy-N-methylphenethylamine; Pituitary Adenylate Cyclase-Activating Polypeptide; Progesterone; Radioimmunoassay; Salamandridae; Type C Phospholipases | 1997 |
Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs.
Topics: Adenosine; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chymases; Cyclosporine; Diclofenac; Histamine Release; Humans; Immunoglobulin E; Immunosuppressive Agents; Leukotriene C4; Mast Cells; Methotrexate; Middle Aged; Polyenes; Prostaglandins D; Rheumatic Diseases; Serine Endopeptidases; Sirolimus; Substance P; Sulfonamides; Synovial Membrane; Tacrolimus; Tryptases | 1997 |
Long-term renal preservation and prevention of acute tubular necrosis by inhibition of arachidonate metabolism.
Topics: Adenosine; Allopurinol; Animals; Arachidonic Acid; Aspirin; Benzofurans; Dogs; Enzyme Inhibitors; Female; Glutathione; Ibuprofen; Imidazoles; Insulin; Kidney Transplantation; Kidney Tubular Necrosis, Acute; Kidney Tubules; Leukotriene Antagonists; Leukotrienes; Organ Preservation; Organ Preservation Solutions; Pyridines; Raffinose; Thromboxane-A Synthase | 1995 |
Nitric oxide-independent dilation of conductance coronary arteries to acetylcholine in conscious dogs.
Topics: Acetylcholine; Adenosine; Animals; Aspirin; Coronary Circulation; Coronary Vessels; Dogs; NG-Nitroarginine Methyl Ester; Nitric Oxide; Proadifen; Quinacrine; Vasodilation | 1997 |
[New discoveries on adenosis and prostacyclin. Physiological processes are surveyed in genetic elimination trials].
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Epoprostenol; Humans; Receptors, Prostaglandin; Receptors, Purinergic P1 | 1997 |
The lack of bimodality in the effects of endogenous and exogenous prostaglandins on fat cell lipolysis in rats.
Topics: Adenosine; Adenosine Deaminase; Adipocytes; Adrenergic beta-Agonists; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Epoprostenol; Female; Glycerol; Indomethacin; Isoproterenol; Lipolysis; Rats; Rats, Wistar | 1998 |
Contribution of vasodilator prostanoids and nitric oxide to resting flow, metabolic vasodilation, and flow-mediated dilation in human coronary circulation.
Topics: Adenosine; Adult; Aged; Aspirin; Coronary Circulation; Female; Humans; Male; Middle Aged; Nitric Oxide; omega-N-Methylarginine; Prostaglandins; Vascular Resistance; Vasodilation | 1999 |
Alert to physicians: possible interaction of aggrenox and adenosine.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Drug Interactions; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Vasodilator Agents | 2000 |
Aggrenox and stress testing.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Humans; Ischemia; Platelet Aggregation Inhibitors; Stroke; Vasodilator Agents | 2001 |
Adenosine and Aggrenox: a hazardous combination.
Topics: Adenosine; Aged; Aspirin; Aspirin, Dipyridamole Drug Combination; Bradycardia; Delayed-Action Preparations; Dipyridamole; Drug Combinations; Drug Interactions; Female; Heart; Humans; Radionuclide Imaging | 2002 |
Prevention by parenteral aspirin of indomethacin-induced gastric lesions in rats: mediation by salicylic acid.
Topics: Adenosine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Gastric Mucosa; Gastrointestinal Motility; Indomethacin; Injections, Subcutaneous; Male; Rats; Rats, Sprague-Dawley; Salicylic Acid | 2002 |
[Inhibition of adenosine deaminase activity by drugs influencing the cardiovascular system].
Topics: Adenosine; Adenosine Deaminase Inhibitors; Animals; Aspirin; Cardiovascular Agents; Cardiovascular System; Deoxyadenosines; Female; Fibrinolytic Agents; Isoenzymes; Isosorbide Dinitrate; Male; Metoprolol; Molsidomine; Rabbits; Random Allocation; Simvastatin; Vasodilator Agents; Vasomotor System | 2004 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Thiophenes; Ticagrelor; Ticlopidine | 2008 |
Test before you stop.
Topics: Adenosine; Algorithms; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Perioperative Care; Piperazines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prasugrel Hydrochloride; Pyridines; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2009 |
P2Y12 inhibitors: thienopyridines and direct oral inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Atherosclerosis; Coronary Artery Bypass; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Stroke; Thiophenes; Ticagrelor | 2009 |
Changes in platelets and anticoagulant protein activity during adenosine-exercise single-photon emission computed tomography stress test.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aged; Antithrombins; Aspirin; beta-Thromboglobulin; Blood Coagulation; Clopidogrel; Coronary Stenosis; Epinephrine; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Factor 4; Protein C; Ticlopidine; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2010 |
Conversion of Th17-type into Th2-type inflammation by acetyl salicylic acid via the adenosine and uric acid pathway in the lung.
Topics: Adenosine; Allergens; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Disease Models, Animal; Humans; Inflammation; Lipopolysaccharides; Lung; Mice; Mice, Inbred C57BL; Th17 Cells; Th2 Cells; Uric Acid | 2010 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug Therapy, Combination; Emergency Medicine; Hemorrhage; Hospitalists; Humans; Imines; Lactones; Patient Selection; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Pyridines; Receptor, PAR-1; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Topics: Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Electrocardiography; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2010 |
[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2010 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Approval; Humans; Multicenter Studies as Topic; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Thrombosis; Ticagrelor; Ticlopidine; United States | 2011 |
Resistance to anti-platelet agents.
Topics: Adenosine; Aspirin; Clopidogrel; Drug Resistance; Humans; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Aspirin dose and ticagrelor benefit in PLATO: fact or fiction?
Topics: Adenosine; Aspirin; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2010 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Lactones; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Pyridines; Quinazolinones; Randomized Controlled Trials as Topic; Receptor, PAR-1; Sulfonamides; Ticagrelor; Ticlopidine | 2011 |
Assessment of statistical heterogeneity in the PLATO trial.
Topics: Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors | 2011 |
Antiplatelet effects of aspirin vary with level of P2Y₁₂ receptor blockade supplied by either ticagrelor or prasugrel.
Topics: Adenosine; Aspirin; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor | 2011 |
Ticagrelor approved for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Approval; Drug Labeling; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2011 |
Ticagrelor (Brilinta)--better than clopidogrel (Plavix)?
Topics: Adenosine; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Approval; Drug Interactions; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticagrelor; Ticlopidine; United States | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Drug-Eluting Stents; Electrocardiography; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2012 |
Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor co-administered with aspirin in healthy volunteers.
Topics: Adenosine; Adenosine Diphosphate; Adult; Aspirin; Bleeding Time; Clopidogrel; Collagen; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine; Young Adult | 2013 |
High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Topics: Adenosine; Animals; Arachidonic Acid; Aspirin; Clopidogrel; Dogs; Dose-Response Relationship, Drug; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Thrombosis; Ticagrelor; Ticlopidine; Vascular Resistance | 2013 |
Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Abnormalities; Diabetes Mellitus; Drug Interactions; Drug Labeling; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Ticagrelor; United States; United States Food and Drug Administration | 2013 |
Evidenced-based antithrombotic therapy for acute coronary syndromes.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus; Drug Labeling; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2013 |
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Decision Trees; Drug Costs; Humans; Markov Chains; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Quality-Adjusted Life Years; Republic of Korea; Singapore; Ticagrelor; Ticlopidine | 2013 |
Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.
Topics: Adenosine; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Pharmacogenetics; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Polymorphism, Single Nucleotide; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endothelium, Vascular; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Peripheral Arterial Disease; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Refuting the ticagrelor-aspirin black box warning: and proposing a ticagrelor early-PCI black box warning.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Time Factors | 2013 |
High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arteries; Aspirin; Dose-Response Relationship, Drug; Endothelium, Vascular; Male; Muscle Contraction; Myocytes, Smooth Muscle; Rats; Tail; Ticagrelor; Vasoconstriction | 2013 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials, Phase III as Topic; Clopidogrel; Double-Blind Method; Female; Gastrointestinal Hemorrhage; Gastrointestinal Neoplasms; Humans; Kaplan-Meier Estimate; Male; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2013 |
Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Transfusion; Ticagrelor; Ticlopidine | 2014 |
Perioperative outcomes of cardiac surgery patients with ongoing ticagrelor therapy: boon and bane of a new drug.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Blood Transfusion; Coronary Artery Bypass; Female; Hemorrhage; Humans; Male; Middle Aged; Perioperative Period; Platelet Aggregation Inhibitors; Retrospective Studies; Ticagrelor; Treatment Outcome | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Smoking; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2013 |
Spontaneous omental bleeding in the setting of dual anti-platelet therapy with ticagrelor.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine | 2014 |
Initial experience with ticagrelor in patients with critical limb ischemia and high on-clopidogrel platelet reactivity undergoing complex peripheral endovascular procedures.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Endovascular Procedures; Female; Follow-Up Studies; Humans; Leg; Limb Salvage; Male; Middle Aged; Peripheral Vascular Diseases; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Survival Rate; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
A case of pulmonary hemorrhage due to drug-induced pneumonitis secondary to ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biopsy; Coronary Artery Bypass; Diagnosis, Differential; Hemoptysis; Humans; Lung; Male; Middle Aged; Platelet Aggregation Inhibitors; Pneumonia; Purinergic P2Y Receptor Antagonists; Ticagrelor; Tomography, X-Ray Computed | 2014 |
Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery.
Topics: Adenosine; Aspirin; Blood Platelets; Clopidogrel; Consensus; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Preoperative Care; Purinergic P2Y Receptor Antagonists; Risk Assessment; Risk Factors; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Subacute bioresorbable vascular scaffold thrombosis: a report of 2 cases.
Topics: Absorbable Implants; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary Thrombosis; Coronary Vessels; Drug-Eluting Stents; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Syncope during a pharmacologic nuclear stress test.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Drug Interactions; Exercise Test; Female; Heart Arrest; Humans; Middle Aged; Platelet Aggregation Inhibitors; Radiopharmaceuticals; Syncope | 2014 |
A serious complication of a common stress test (May 2014).
Topics: Adenosine; Aspirin; Dipyridamole; Female; Heart Arrest; Humans; Platelet Aggregation Inhibitors; Radiopharmaceuticals; Syncope | 2014 |
In reply.
Topics: Adenosine; Aspirin; Dipyridamole; Female; Heart Arrest; Humans; Platelet Aggregation Inhibitors; Radiopharmaceuticals; Syncope | 2014 |
Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Aspirin; Cardiotonic Agents; Clopidogrel; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Evaluation, Preclinical; Enzyme Induction; Lipoxins; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase Type III; Pyrazoles; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A1; Receptor, Adenosine A2A; Ticagrelor; Ticlopidine; Triazoles; Up-Regulation | 2014 |
Short bowel syndrome and clopidogrel non-responsiveness: a new indication for platelet aggregometry?
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Drug Resistance; Drug Therapy, Combination; Female; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Short Bowel Syndrome; Ticagrelor; Ticlopidine | 2014 |
[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Quality of Life; Spain; Ticagrelor; Ticlopidine; Time Factors | 2014 |
Platelet aggregation and clot formation in comatose survivors of cardiac arrest treated with induced hypothermia and dual platelet inhibition with aspirin and ticagrelor; a prospective observational study.
Topics: Adenosine; Adult; Aged; Aspirin; Blood Platelets; Coma; Combined Modality Therapy; Drug Therapy, Combination; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Middle Aged; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Ticagrelor | 2014 |
Very late bioresorbable vascular scaffold thrombosis following discontinuation of antiplatelet therapy.
Topics: Absorbable Implants; Adenosine; Adult; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Graft Occlusion, Vascular; Humans; Male; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine; Tirofiban; Tissue Scaffolds; Tyrosine | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Coronary Artery Disease; Female; Graft Occlusion, Vascular; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Precision Medicine; Prospective Studies; Registries; Stents; Thiophenes; Ticagrelor; Ticlopidine | 2014 |
Temperature effects on haemostasis in whole blood from ticagrelor- and aspirin-treated patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Case-Control Studies; Combined Modality Therapy; Female; Hemostasis; Homeostasis; Humans; Hypothermia, Induced; Male; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Treatment Outcome | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; Female; Fibrinolytic Agents; Hemorrhage; Humans; Male; Middle Aged; Retrospective Studies; Risk Factors; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome; Warfarin | 2015 |
Predictors of high on-aspirin platelet reactivity in high-risk vascular patients treated with single or dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Cerebrovascular Disorders; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Fibrinogen; Humans; Male; Middle Aged; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Secondary Prevention; Thiophenes; Ticagrelor; Ticlopidine | 2015 |
Balancing the risks and benefits of dual platelet inhibition.
Topics: Adenosine; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibitors; Thiophenes; Thrombosis; Ticagrelor; Ticlopidine | 2015 |
Antiplatelet and invasive treatment in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and acute coronary syndrome. The safety of aspirin.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Glucosephosphate Dehydrogenase Deficiency; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor | 2015 |
Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies.
Topics: Adenosine; Adult; Animals; Arteriovenous Shunt, Surgical; Aspirin; Blood Coagulation; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Rivaroxaban; Thrombin; Ticagrelor; Ticlopidine | 2015 |
Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Percutaneous dilatational tracheostomy in a patient on antiplatelet therapy with ticagrelor and Aspirin: a case report.
Topics: Adenosine; Aspirin; Blood Loss, Surgical; Dilatation; Female; Humans; Middle Aged; Platelet Aggregation Inhibitors; Ticagrelor; Tracheostomy | 2015 |
Platelet inhibition with ticagrelor for left ventricular assist device thrombosis.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Drug Therapy, Combination; Heart Failure; Heart-Assist Devices; Heparin; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prosthesis Design; Thrombosis; Ticagrelor; Treatment Outcome; Ventricular Function, Left | 2015 |
Lack of Effect of Platelet Transfusions and Desmopressin on Intracranial Bleeding in a Patient Receiving Ticagrelor.
Topics: Adenosine; Aged; Aspirin; Combined Modality Therapy; Deamino Arginine Vasopressin; Fatal Outcome; Hemostatics; Humans; Intracranial Hemorrhages; Male; Myocardial Infarction; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2015 |
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Body Mass Index; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Male; Mean Platelet Volume; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
Risk stratification for secondary prevention with ticagrelor and aspirin: A closer look to patient subsets from the PEGASUS-TIMI 54 trial.
Topics: Adenosine; Aged; Aspirin; Female; Humans; Male; Myocardial Infarction; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Secondary Prevention; Ticagrelor; Treatment Outcome | 2015 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mortality; Neoplasms; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Sepsis; Ticagrelor; Ticlopidine | 2015 |
The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: An in-vitro study.
Topics: Adenosine; Adenosine Diphosphate; Arachidonic Acid; Aspirin; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Platelet Transfusion; Ticagrelor | 2016 |
Dual antiplatelet therapy use by Canadian cardiac surgeons.
Topics: Adenosine; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Ticagrelor; Ticlopidine | 2015 |
Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2015 |
[The PEGASUS-TIMI 54 study].
Topics: Adenosine; Aspirin; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor | 2015 |
Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Adenosine; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; Odds Ratio; Patient Discharge; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prevalence; Thrombosis; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Impact of atorvastatin or rosuvastatin co-administration on platelet reactivity in patients treated with dual antiplatelet therapy.
Topics: Adenosine; Aged; Aspirin; Atorvastatin; Chi-Square Distribution; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Polypharmacy; Risk Assessment; Risk Factors; Rosuvastatin Calcium; Ticagrelor; Ticlopidine; Treatment Outcome | 2015 |
Use of ticagrelor in human pregnancy, the first experience.
Topics: Adenosine; Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications; Purinergic P2Y Receptor Antagonists; Secondary Prevention; Thromboembolism; Ticagrelor | 2015 |
Stent thrombosis after primary percutaneous coronary intervention in comatose survivors of out-of-hospital cardiac arrest: Are the new P2Y12 inhibitors really more effective than clopidogrel?
Topics: Adenosine; Aspirin; Clopidogrel; Coma; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Out-of-Hospital Cardiac Arrest; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Retrospective Studies; Risk Factors; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Diffuse alveolar hemorrhage associated with low molecular weight heparin and dual anti-platelet therapy after percutaneous coronary intervention.
Topics: Adenosine; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combination; Fatal Outcome; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Pulmonary Alveoli; Purinergic P2Y Receptor Antagonists; Risk Factors; Stents; Thrombosis; Ticagrelor | 2017 |
Ticagrelor in the Real World: The Midland Regional Cardiac Network Experience.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adherence; Myocardial Infarction; Patient Satisfaction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor | 2015 |
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Ticagrelor; Ticlopidine | 2016 |
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2016 |
[How long should therapy last?].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; Humans; Long-Term Care; Platelet Aggregation Inhibitors; Ticagrelor | 2015 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Secondary Prevention; Ticagrelor; Ticlopidine; Time Factors | 2016 |
Prevalence and Prognosis of High-risk Myocardial Infarction Patient Candidates to Extended Antiplatelet Therapy.
Topics: Adenosine; Age Factors; Aged; Aged, 80 and over; Aspirin; Diabetes Mellitus; Drug Therapy, Combination; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Patient Selection; Platelet Aggregation Inhibitors; Prevalence; Prognosis; Proportional Hazards Models; Renal Insufficiency, Chronic; Risk Assessment; Secondary Prevention; Spain; Ticagrelor; Time Factors | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Databases, Factual; Drug Resistance; Drug Therapy, Combination; Female; Homeodomain Proteins; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Transcription Factors; Treatment Outcome; Up-Regulation | 2016 |
Editorial on PEGASUS - TIMI 54.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Ticagrelor; Treatment Outcome | 2016 |
[Dual platelet inhibition - for how long?].
Topics: Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Drug Therapy, Combination; Evidence-Based Medicine; Guideline Adherence; Humans; Ischemic Attack, Transient; Long-Term Care; Platelet Aggregation Inhibitors; Postoperative Care; Stents; Ticagrelor | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Risk Factors; Ticagrelor; Ticlopidine; Time Factors; Treatment Outcome; Up-Regulation; Uric Acid | 2016 |
Initiation and persistence with dual antiplatelet therapy after acute myocardial infarction: a Danish nationwide population-based cohort study.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Denmark; Drug Prescriptions; Drug Therapy, Combination; Female; Humans; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2016 |
Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment.
Topics: Adenosine; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Care; Postoperative Hemorrhage; Preoperative Care; Retrospective Studies; Ticagrelor; Ticlopidine | 2016 |
Diabetes mellitus, glucose control parameters and platelet reactivity in ticagrelor treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Glucose; Blood Platelets; Diabetes Complications; Diabetes Mellitus; Female; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor | 2016 |
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; ST Elevation Myocardial Infarction; Survival Analysis; Ticagrelor; Ticlopidine | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Israel; Male; Middle Aged; Multivariate Analysis; Percutaneous Coronary Intervention; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Registries; Stents; Stroke; Survival Analysis; Thrombosis; Ticagrelor; Ticlopidine | 2016 |
Prolonged dual antiplatelet therapy in stable coronary disease: comparative observational study of benefits and harms in unselected versus trial populations.
Topics: Adenosine; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Drug Therapy, Combination; Electronic Health Records; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Secondary Prevention; Stroke; Ticagrelor; Time Factors | 2016 |
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
Ticagrelor for left ventricular assist device thrombosis: A new therapeutic option to be evaluated with caution.
Topics: Adenosine; Aged; Aspirin; Blood Coagulation; Cardiomyopathies; Clopidogrel; Drug Substitution; Drug Therapy, Combination; Fibrinolytic Agents; Heart-Assist Devices; Humans; Male; Medication Therapy Management; Postoperative Complications; Risk Adjustment; Thrombosis; Ticagrelor; Ticlopidine; Treatment Outcome | 2016 |
The Effect of Antiplatelet Agents on Bleeding-Related Complications After Ureteroscopy.
Topics: Adenosine; Adult; Aged; Anticoagulants; Aspirin; Blood Platelets; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Risk; Ticagrelor; Ticlopidine; Ureteroscopy | 2016 |
NICE recommends ticagrelor with aspirin for three years post-MI.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Secondary Prevention; Ticagrelor; United Kingdom | 2016 |
In acute stroke or TIA, ticagrelor did not differ from aspirin for a composite of stroke, MI, or death at 90 days.
Topics: Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2016 |
Optimal duration of dual anti-platelet therapy after percutaneous coronary intervention: 2016 consensus position of the Italian Society of Cardiology.
Topics: Adenosine; Aspirin; Cardiology; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Italy; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Societies, Medical; Thrombosis; Ticagrelor | 2017 |
Spontaneous coronary artery dissection in a young woman with polycystic ovarian syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Chest Pain; Coronary Angiography; Coronary Vessel Anomalies; Coronary Vessels; Electrocardiography; Female; Humans; Platelet Aggregation Inhibitors; Polycystic Ovary Syndrome; Purinergic P2Y Receptor Antagonists; Ticagrelor; Vascular Diseases | 2017 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Recurrence; Risk Factors; Ticagrelor; Ticlopidine | 2017 |
Letter by Moris et al Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes)".
Topics: Adenosine; Aspirin; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
Response by Wang and Johnston to Letter Regarding Article, "Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcom
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke; Ticagrelor; Ticlopidine | 2017 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; Female; Hospitalization; Humans; Incidence; Male; Medication Therapy Management; Patient Discharge; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Survival Analysis; Ticagrelor; Ticlopidine | 2017 |
Triple Antithrombotic Therapy With Aspirin, P2Y12 Inhibitor, and Warfarin After Percutaneous Coronary Intervention: An Evaluation of Prasugrel or Ticagrelor Versus Clopidogrel.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Drug Therapy, Combination; Female; Hemorrhage; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Ticagrelor; Warfarin | 2017 |
Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies.
Topics: Adenosine; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Case-Control Studies; Coronary Artery Disease; Drug Therapy, Combination; Half-Life; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Thienopyridines; Thrombopoiesis; Ticagrelor; Young Adult | 2017 |
Hemostatic effects of the ticagrelor antidote MEDI2452 in pigs treated with ticagrelor on a background of aspirin.
Topics: Adenosine; Adenosine Diphosphate; Animals; Antibodies, Neutralizing; Antidotes; Aspirin; Biotinylation; Blood Pressure; Broadly Neutralizing Antibodies; Hemorrhage; Hemostasis; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Swine; Ticagrelor; Time Factors | 2017 |
Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™.
Topics: Adenosine; Aged; Aspirin; Carotid Artery, Internal; Cerebral Angiography; Clopidogrel; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Stroke; Ticagrelor; Ticlopidine | 2017 |
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Reproducibility of Results; Signal Transduction; Stents; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Drug Resistance; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Heterozygote; Homozygote; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Percutaneous Coronary Intervention; Pharmacogenetics; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenotype; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Ticagrelor; Ticlopidine; Treatment Outcome; Vitamin D Deficiency; Vitamin D-Binding Protein | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospital Mortality; Humans; Male; Middle Aged; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prescription Drugs; Prospective Studies; Purinergic P2Y Receptor Antagonists; Registries; Ticagrelor; Ticlopidine | 2017 |
Investigating therapeutic usage of combined Ticagrelor and Aspirin through solid-state and analytical studies.
Topics: Adenosine; Aspirin; Calorimetry, Differential Scanning; Chromatography, High Pressure Liquid; Drug Combinations; Drug Stability; Mass Spectrometry; Platelet Aggregation Inhibitors; Powder Diffraction; Spectroscopy, Fourier Transform Infrared; Thermogravimetry; Ticagrelor; X-Ray Diffraction | 2017 |
Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcome
Topics: Adenosine; Aged; Aspirin; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Male; Purinergic P2Y Receptor Antagonists; Risk; Stroke; Ticagrelor; Treatment Outcome | 2017 |
Repetitive stent thrombosis in a patient with suspected allergy to aspirin and multiple switch between clopidogrel, prasugrel, and ticagrelor.
Topics: Adenosine; Aspirin; Clopidogrel; Coronary Vessels; Drug Hypersensitivity; Humans; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Recurrence; Stents; Thrombosis; Ticagrelor; Ticlopidine | 2017 |
The impact of CYP2C19*2, CYP4F2*3, and clinical factors on platelet aggregation, CYP4F2 enzyme activity, and 20-hydroxyeicosatetraenoic acid concentration in patients treated with dual antiplatelet therapy.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Cytochrome P450 Family 4; Female; Humans; Hydroxyeicosatetraenoic Acids; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Safety of Antiplatelet Agents: Analysis of 'Real-World' Data from the Italian National Pharmacovigilance Network.
Topics: Adenosine; Adult; Aged; Aged, 80 and over; Aspirin; Female; Hemorrhage; Humans; Italy; Male; Middle Aged; Pharmacovigilance; Platelet Aggregation Inhibitors; Pyridines; Ticagrelor | 2017 |
Microfludic platforms for the evaluation of anti-platelet agent efficacy under hyper-shear conditions associated with ventricular assist devices.
Topics: Adenosine; Aspirin; Drug Evaluation, Preclinical; Heart-Assist Devices; Lab-On-A-Chip Devices; Platelet Aggregation Inhibitors; Shear Strength; Sonication; Ticagrelor | 2017 |
A Prospective Evaluation of a Pre-Specified Absorb BVS Implantation Strategy in ST-Segment Elevation Myocardial Infarction: The BVS STEMI STRATEGY-IT Study.
Topics: Absorbable Implants; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Coronary Thrombosis; Drug Therapy, Combination; Female; Humans; Italy; Male; Middle Aged; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Prospective Studies; Prosthesis Design; Recurrence; Risk Factors; ST Elevation Myocardial Infarction; Ticagrelor; Time Factors; Treatment Outcome | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Decreased platelet inhibition by P2Y12 receptor blockers in anaemia.
Topics: Adenosine; Adenosine Diphosphate; Aged; Anemia; Angioplasty; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Monocytes; P-Selectin; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Ticagrelor; Ticlopidine | 2018 |
[Clinical effectiveness and safety of ticagrelor in patients after PCI because of acute non ST segment elevation myocardial infarction].
Topics: Adenosine; Aspirin; China; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Thrombolytic Therapy; Ticagrelor; Ticlopidine; Treatment Outcome | 2017 |
EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Coronary Vessels; Disease-Free Survival; Drug Therapy, Combination; Female; Fibrinolytic Agents; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Myocardial Revascularization; Plaque, Atherosclerotic; Platelet Aggregation Inhibitors; Predictive Value of Tests; Prospective Studies; Risk Factors; Thrombectomy; Ticagrelor; Time Factors; Tomography, Optical Coherence; Treatment Outcome | 2017 |
Evaluation of platelet activity by multiple electrode impedance aggregometry in acute coronary syndromes: pilot study in a Brazilian tertiary-care public hospital.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Electric Impedance; Female; Hospitals, Public; Humans; Male; Pilot Projects; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Count; Platelet Function Tests; Prospective Studies; Receptors, Purinergic P2Y12; Tertiary Care Centers | 2019 |
Bioactive carbon dots direct the osteogenic differentiation of human bone marrow mesenchymal stem cells.
Topics: Adenosine; Alkaline Phosphatase; Animals; Aspirin; Biocompatible Materials; Bone Marrow Cells; Carbon; Cell Death; Cell Differentiation; Humans; Male; Mesenchymal Stem Cells; Mice, Inbred ICR; Osteogenesis | 2019 |
Gender Differences in Platelet Reactivity in Diabetic Patients Receiving Dual Antiplatelet Therapy.
Topics: Adenosine; Aftercare; Aspirin; Blood Platelets; Diabetes Mellitus; Drug Therapy, Combination; Female; Humans; Male; Patient Discharge; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Sex Characteristics; Ticlopidine | 2020 |
Cilostazol increases adenosine plasma concentration in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; China; Cilostazol; Clopidogrel; Cyclic AMP; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Function Tests | 2021 |
Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Topics: Acute Coronary Syndrome; Adenosine; Arachidonic Acid; Aspirin; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Ticlopidine; Treatment Outcome | 2021 |
FDA PLATO deaths list challenges aspirin dose-ticagrelor interaction.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Ticagrelor; Treatment Outcome | 2021 |
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Blood Platelets; Clopidogrel; Humans; Obesity; Overweight; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Ticagrelor; Ticlopidine | 2023 |
Aspirin with Low-Dose Ticagrelor or with Low-Dose Rivaroxaban for Secondary Prevention: A Cost per Outcome Analysis.
Topics: Adenosine; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Rivaroxaban; Secondary Prevention; Ticagrelor; Treatment Outcome | 2022 |
Platelet function testing using the Multiplate analyzer after administration of aspirin in Aachen minipigs.
Topics: Adenosine; Adenosine Diphosphate; Animals; Arachidonic Acid; Aspirin; Blood Platelets; Diphosphates; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Receptors, Thrombin; Swine; Swine, Miniature | 2022 |
High-Intensity Exercise Training Improves Basal Platelet Prostacyclin Sensitivity and Potentiates the Response to Dual Anti-Platelet Therapy in Postmenopausal Women.
Topics: Adenosine; Adenosine Diphosphate; Aspirin; Cyclooxygenase 1; Diphosphates; Dual Anti-Platelet Therapy; Epoprostenol; Estrogens; Exercise; Female; Humans; Nitric Oxide; Peptides; Platelet Aggregation Inhibitors; Postmenopause; Receptors, Epoprostenol; Receptors, Thromboxane; Thrombin; Thrombosis; Thromboxanes | 2022 |
The impact of high on-treatment platelet reactivity and fibrinogen levels on ischemic events in patients with ST elevation myocardial infarction: a prospective observational study.
Topics: Adenosine; Aspirin; Clopidogrel; Fibrinogen; Humans; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; ST Elevation Myocardial Infarction; Ticagrelor; Ticlopidine; Treatment Outcome | 2023 |
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Humans; Male; Pandemics; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Ticagrelor; Ticlopidine; Treatment Outcome | 2022 |
Aspirin ameliorates atherosclerotic immuno-inflammation through regulating the Treg/Th17 axis and CD39-CD73 adenosine signaling via remodeling the gut microbiota in ApoE
Topics: Adenosine; Animals; Apolipoproteins E; Aspirin; Atherosclerosis; Gastrointestinal Microbiome; Inflammation; Mice; Signal Transduction; T-Lymphocytes, Regulatory; Th17 Cells | 2023 |